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ABSTRACT
YUFAN ZHAO: Reinforcement Learning Design for Cancer Clinical Trials
(Under the direction of Dr. Michael Kosorok)
There has been significant recent research activity in developing therapies that are
tailored to each individual. Finding such therapies in treatment settings involving mul-
tiple decision times is a major challenge. In this dissertation, we develop reinforcement
learning trials for discovering these optimal regimens for life-threatening diseases such as
cancer. A temporal-difference learning method calledQ-learning is utilized which involves
learning an optimal policy from a single training set of finite longitudinal patient trajec-
tories. Approximating the Q-function with time-indexed parameters can be achieved by
using support vector regression or extremely randomized trees. Within this framework,
we demonstrate that the procedure can extract optimal strategies directly from clinical
data without relying on the identification of any accurate mathematical models, unlike
approaches based on adaptive design. We show that reinforcement learning has tremen-
dous potential in clinical research because it can select actions that improve outcomes
by taking into account delayed effects even when the relationship between actions and
outcomes is not fully known.
To support our claims, the methodology’s practical utility is firstly illustrated in a
virtual simulated clinical trial. We then apply this general strategy with significant re-
finements to studying and discovering optimal treatments for advanced metastatic stage
IIIB/IV non-small cell lung cancer (NSCLC). In addition to the complexity of the NSCLC
problem of selecting optimal compounds for first and second-line treatments based on
prognostic factors, another primary scientific goal is to determine the optimal time to ini-
iii
tiate second-line therapy, either immediately or delayed after induction therapy, yielding
the longest overall survival time. We show that reinforcement learning not only success-
fully identifies optimal strategies for two lines of treatment from clinical data, but also
reliably selects the best initial time for second-line therapy while taking into account
heterogeneities of NSCLC across patients.
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1 Introduction
Discovering effective therapeutic regimens for life-threatening diseases is one of the central
goals of medical research. Finding powerful and general methodologies for accomplish-
ing this discovery is a major challenge. The prevailing approach is to develop candidate
therapies in the laboratory using basic science and then to test those therapies in animals
and then in human clinical trials. A major problem is that very few candidate treatments
make it to human clinical trials and only about 10% of treatments making it to human
clinical trials demonstrate enough efficacy to be approved for marketing (Hogberg, 2005;
Food and Drug Administration, 2004). Typical regimens for some advanced cancer (such
as breast cancer, lung cancer, and ovarian cancer) patients utilize a single agent in combi-
nation with some platinum-based compound, and consist of multiple stages of treatment
(especially when relapse is common). For example, many studies demonstrate that three
lines of treatment can improve survival for patients with advanced non-small cell lung
cancer (NSCLC). For patients who present with a good performance status and stage
IIIB/IV disease, platinum-based chemotherapy is the primary treatment which can offer
a modest survival advantage over best supportive care alone. Approximately 50–60% of
patients in recent first-line trials received second-line treatment (Sandler et al., 2006).
Some patients who maintain a good performance status and tolerate therapy without
significant toxicities will receive third-line therapy (Stinchcombe and Socinski, 2008).
A widely used approach is to give a maximum dosage of chemotherapy drug for some
period of time, followed by a period of recuperation in which no drug is given. Although
this therapeutic regimen can be easily clinically implemented, this may not be the best
strategy for minimizing tumor burden. Such problems have motivated the vast literature
on drug-scheduling strategies. In the past few years, there has been extensive research on
applications of adaptive design to clinical trials. Many investigators have developed var-
ious adaptive designs to efficiently identify clinical benefits of the treatment, and demon-
strated that conducting adaptive designs can be very promising in clinical development.
In general, adaptive designs for multiple courses of chemotherapy allow modification of
randomization schedules based on varied probabilities of treatment assignment in order to
increase the probability of success. In choosing treatments for successive courses, one of
the popular adaptive designs to do this is the play-the-winner-and-drop-the-loser design,
which is to repeat a treatment that is successful in a given course and otherwise switch to
a different treatment. Thall, Millikan, and Sung (2000) provided a statistical framework
for multi-course clinical trials involving some modifications of the play-the-winner-and-
drop-the-loser strategy. In their proposed design, all treatments after the first course
are assigned adaptively, thus increasing the amount of information available per patient.
Thall et al. (2007) presented a Bayesian adaptive design for a trial comparing two-course
strategies for treating metastatic renal cancer. Each patient is fairly randomized between
two treatments at enrollment, and if a patient suffers a disease progression (s)he is then
re-randomized among three treatments not given initially. One of the common features
of these adaptive designs is the use of parametric models accounting for efficacy, toxicity,
or time to some events (such as survival time). By defining a probability model, it’s easy
to study the design’s operating characteristics under a range of parameterizations and
clinical scenarios. However, as a result, it will lead to all individuals being assigned to
the same level and type of treatment. Therefore, the limitation is not only to ignore the
heterogeneity in treatment across individuals, but also to unsuccessfully incorporate the
heterogeneity needed for optimal individualized treatment across time.
In addition to the challenge of taking into account accrued information in clinical trial
designs, another major challenge is the examination of the long-term benefit of treatment
due to delayed effects. If we consider the larger context of the overall therapeutic strategy,
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in many clinical settings a regimen with a lower initial response rate still can be the best
choice in the long run. This is quite plausible due to the potential for the regimen’s
comparatively better delayed clinical benefit. For finding new treatment regimens with
this motivation, one of the most promising approaches has been referred to variously as
“dynamic treatment regimes” or “adaptive treatment strategies” (Murphy, 2005a). In
contrast with classic adaptive designs, dynamic treatment regimes can allow dosage level
and type to vary with time for subject-specific needs. As a consequence, the optimal
strategy is able to provide information not only on the best treatment choice from the
beginning but also treatment choices that maximize outcomes for a later time. Dynamic
treatment regimes are recently emerging as a new paradigm for the treatment and long
term management of chronic disease, and they have been utilized in some trials such as
sequential multiple assignment randomized trials (SMART) (Murphy, 2005a) and drug
and alcohol dependency studies (Murphy et al., 2007a). However, to date, there are no
clinical trial methodologies for discovering new treatment regimens for life-threatening
diseases. Thus, for diseases like cancer, the use of clinical trials for evaluation and not
discovery remains the prevailing paradigm.
Over the last few decades, machine learning has become an active branch of artificial
intelligence. Some of the fields studied in machine learning involve stochastic sequen-
tial decision processes, commonly referred to as reinforcement learning methods. The
term “reinforcement” comes from studies of animal learning in experimental psychology,
where it refers to the occurrence of an event, in the proper relation to a response, that
tends to increase the probability that the response will occur again in the same situation.
The standard reinforcement learning method considers a performance agent operating in
discrete time, observing at time t the environmental state xt, taking an action at, and
receiving back information from the environment (the next state xt+1 and the instanta-
neous reward rt). The basic process of reinforcement learning involves trying a sequence
at of actions, recording the consequences rt of those actions, statistically estimating the
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relationship between at and rt, and then choosing the action that results in the most
desirable consequence.
In this dissertation, we present a general reinforcement learning framework and related
statistical and computational methods for use in the clinical research arena. Reinforce-
ment learning has been applied to treating behavioral disorders, where each patient typi-
cally has multiple opportunities to try different treatments (Pineau et al., 2007). Murphy
et al. (2007b) suggest Q-learning, which is one of the most important breakthroughs in
reinforcement learning, for constructing decision rules for chronic psychiatric disorders,
since these chronic conditions often require sequential decision making to achieve the
best clinical outcomes. Moreover, reinforcement learning has been successfully applied
to the segmentation of the prostate in transrectal ultrasound images. Due to its use of
knowledge obtained from the previous input image, the reinforcement learning algorithm
is potentially capable of finding the appropriate local value for sub-images and extract-
ing the prostate image (Sahba, Tizhoosh, and Salama, 2008). However, reinforcement
learning has not yet been applied to life-threatening diseases like cancer where individual
patients do not have the luxury to try many different treatments. Our main aim is to
illustrate the application of these methods to the discover of new treatment regimens
for life-threatening diseases such as cancer. This is a paradigm shift from the standard
clinical trial framework which is used for evaluating treatments but not for discovery. We
consider trials in which each patient is randomized among a set of treatments at each
stage and this treatment set consists of a continuous range of possibilities including, for
example a continuous range of dose levels. Therefore, rather than being constrained to
a finite list of pre-specified treatments, our method allows for more general multiplicities
of treatments which may include a continuum of possibilities at each stage. Reinforce-
ment learning design has two attractive features that make it a useful tool for extracting
optimal strategies directly from clinical data. First, without relying on the identifica-
tion of any accurate mathematical models, it carries out treatment selection sequentially
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with time-dependent outcomes to determine which of several possible next treatments
is best for which patients at each decision time. This feature not only helps us account
for heterogeneity in treatment across individuals, but also possibly captures the best
individualized therapies even when the relationship between treatments and outcomes is
not fully known. Secondly, in contrast to focusing on short-term benefits, the proposed
approach improves longer-term outcomes by considering delayed effect of treatments.
Furthermore, we find that reinforcement learning design can extract the optimal treat-
ment strategies while taking into account a drug’s efficacy and toxicity simultaneously,
which is supported by our simulation studies.
The remainder of this dissertation is organized as follows. In Section 2.1, we provide a
literature review of clinical trial design with particular attention given to adaptive design
and dynamic treatment regimes. We review mathematical models which use optimal
control theory to seek the solution in cancer treatments in Section 2.2.
In Section 3.2, we provide a detailed description of reinforcement learning and Q-
learning. In Section 3.3, we first describe a support vector machine (SVM) method
which makes fitting Q-functions feasible for clinical data sets; and then we discuss one of
the extensions of SVM, support vector regression (SVR), associated with its application
to reinforcement learning, in Section 3.4. Another modern technique for estimating Q-
functions, extremely randomized trees (ERT), is presented in Section 3.5.
In Section 4.1, we first propose to develop a new design and analysis method that
utilizes this special technology for a new kind of clinical trial for cancer, “clinical rein-
forcement trials”. To demonstrate the reinforcement learning’s potential in discovering
optimal therapies, in Section 4.2, we apply our proposed method to a virtual random-
ized sequential trial, which is a simulation study consisting of 1000 patients. This study
examines the performance of reinforcement learning via SVR and demonstrates that the
therapy found using Q-learning is superior to any constant-dose regimen.
In Chapter 5, we specialize our overall approach to advanced metastatic stage IIIB/IV
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NSCLC. By studying an extensive simulation, we refine our model to identify optimal
two-line treatment strategies for an NSCLC trial that includes right censored patients.
In addition, we demonstrate that our method can reliably select the best time to initiate
second-line therapy for NSCLC.
Finally, we summarize our proposed methods in Chapter 6 and discuss some challenges
for future research.
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2 Literature Review
2.1 Adaptive Design and Dynamic Treatment in Clinical Trials
2.1.1 Adaptive Design
Due to steeply rising drug development costs and escalating patient safety concerns, there
is increasing pressure on pharmaceutical companies and clinical researchers to reexamine
traditional clinical trial techniques and increase the efficiency and safety of the clinical
trial process. One potential way to address the challenges that are receiving significant
attention from pharmaceutical companies, regulatory agencies, and clinical researchers
involved is through adaptive designs. In recent years, the use of adaptive design methods
in clinical research and development based on accrued data has become very popular
due to its flexibility and efficiency. For instance, in 2006, the United States Food and
Drug Administration (FDA) released a Critical Path Opportunities List that calls for
advancing innovative trial designs, especially for the use of prior experience or accumu-
lated information in trial design. This shows the encouragement for the use of innovative
adaptive design methods in clinical trials and the potential use of other approaches in
clinical research and development, such as Bayesian approaches in phase II/III studies.
Based on the review of interim data, it is not uncommon to modify a trial or statistical
procedures in the middle of the conduct of clinical trials. The purpose is not only to
efficiently identify clinical benefits of the test treatment under investigation, but also to
increase the probability of success of clinical development. An adaptive design is defined
as a design that allows adaptations to design and statistical procedures of the trial after
its initiation without undermining the validity and integrity of the trial (Chow, Chang,
and Pong, 2005). Many recent publications refer to an adaptive design as a clinical trial
design that uses accumulating data to decide on how to modify aspects of the study as
it continues, without compromising the scientific method (Gallo et al., 2006).
Commonly considered adaptive design methods in clinical trials include, but are
not limited to: adaptive randomization design, group sequential design, sample size
re-estimation design, play-the-winner-and-drop-the-loser design, adaptive dose finding
design, adaptive treatment-switching design, hypothesis-adaptive design, and adaptive
seamless phase II/III trial design. As we mentioned earlier in Chapter 1, we concentrate
on the patient’s treatment which often involves multiple courses of chemotherapy. In
choosing treatments for successive courses, the design common to this is the play-the-
winner-and-drop-the-loser design, which is to repeat a treatment that is successful in a
given course and otherwise switch to a different treatment. Thall et al. (2000) provided
a statistical framework for multi-course clinical trials involving some modifications of
the play-the-winner-and-drop-the-loser strategy. In their proposed design, all treatments
after the first course are assigned adaptively, thus increasing the amount of information
available per patient.
Most adaptive designs for multiple courses of chemotherapy allow modification of
randomization schedules based on varied and/or unequal probabilities of treatment as-
signment in order to increase the probability of success. For instance, a randomized
two-course, three-treatment acute leukemia trial with adaptive randomization has been
developed in a Bayesian framework by Thall, Sung, and Estey (2002). A simulation study
with the goal of selecting one best treatment, or selecting a best ordered pair of treat-
ments has been investigated by Thall et al. (2000). In addition, in a lymphocyte infusion
trial (Thall, Inoue, and Martin, 2002), an adaptive decision process was evaluated by
determining the infusion time that has the highest probability of treatment success. One
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of the common features of all of these adaptive designs is the use of parametric models
accounting for efficacy, toxicity, or time to some events (such as survival time). By defin-
ing a probability model, it is easy to study the design’s operating characteristics under a
range of parameterizations and clinical scenarios; however, all of these approaches will re-
sult in all individuals being assigned to the same level and type of treatment. Therefore,
the limitation of these approaches is not only to ignore the heterogeneity in treatment
across individuals, but also to unsuccessfully incorporate the heterogeneity needed for
optimal individualized treatment across time. Another common feature of all of these
adaptive designs is the use of accrued information. These designs choose all treatments
after the first one adaptively based on the patient’s outcomes in earlier courses, and thus
they don’t waste important information from previous patients. However, in some cases,
treatments may show not only an immediate effect to patients but also a delayed effect
to patients over time. To date, there are no adaptive designs for incorporating delayed
effect in sequential decisions. The lack of these two characteristics in adaptive designs is
the most important motivation for our proposed reinforcement learning design.
2.1.2 Dynamic Treatment Regimes
Dynamic treatment regimes, which are also called adaptive treatment strategies (Murphy,
2005a), are recently emerging as a new paradigm for the treatment and long term man-
agement of chronic disease. In contrast with classic adaptive design, dynamic treatment
regimes can allow dosage level and type to vary with time for subject-specific needs. Dy-
namic treatment regimes have been conducted in some trials such as sequential multiple
assignment randomized trials (SMART) (Murphy, 2005a) and drug and alcohol depen-
dency studies (Murphy et al., 2007a). Murphy (2003) provided a method for estimating
optimal decision rules which will produce the optimal mean response at the end of the
time period for each individual. Robins (2004) proposed models and developed methods
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for making inference about the optimal regime in a multiple courses trial as well.
Using the notation of Murphy (2005a), let a1, a2, . . . , ak be defined as a sequence of
k treatment decisions for each individual patient at time t in {1, 2, . . . , k}. Sj denotes
the patient’s status at the beginning of the time interval j, in other words, it is the
intermediate outcome available after decision aj−1 and prior to decision aj. The response
at the end of the time period is denoted by Y . Thus, the order of event occurrence is
S1, a1, S2, a2, . . . , Sk, ak, Sk+1, Y . Additionally, for convenience, we use a bar sign over a
variable to denote that variable and all past values of the same variable, for example,
S¯j = {S1, S2, . . . Sj} and a¯j = {a1, a2, . . . aj}. Also, an adaptive treatment strategy is a
sequence of decision rules, denoted as d1, d2, . . . , dk. It is important to recognize that each
rule dj is based on the information available at time j, that is, S¯j, a¯j−1, and aj. In many
cases, the backward induction framework (from dynamic programming) is used to find
the optimal decision rules by maximizing mean response for each time point. Formally,
in the simplest case, when k = 2, the optimal adaptive treatment strategy is given by
(d∗1, d
∗
2), where
d∗2(s¯2, a1) = argmax
a2
Ea¯2 [Y |S¯2 = s¯2].
If we define
V2(s¯2; a1) = max
a2
Ea¯2 [Y |S¯2 = s¯2],
then the optimal decision at time 1 could be expressed as follows:
d∗1(s1) = argmax
a1
Ea1 [V2(S¯2; a1)|S1 = s1].
Again, if denote
V1(s1) = max
a1
Ea¯1 [V2(S¯2; a1)|S1 = s1],
then the mean of Y when the optimal rules (d∗1, d
∗
2) are used to assign treatment is given
by
E[V1(S1)] = E
[
max
a1
Ea1
[
max
a2
Ea¯2 [Y |S¯2]|S1
]]
,
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which is consistent with the expectation formula in Robins’s paper. Murphy (2003)
proposed semiparametric methods for estimating the optimal rules through the available
experimental or observational longitudinal data, when the multivariate distribution of
(S¯k, Y ) is unknown. The parametric part was used to estimate those optimal rules
by modeling the regret function, while the second part consisting of high or infinite
dimensional parameters was modelled as a collection of nuisance parameters. Following
Murphy’s first approach, Robins (2004) investigated a number of estimating equations for
finding optimal decision rules using structural nested mean models. Moodie, Richardson,
and Stephens (2007) showed that Murphy’s approach and Robins’s are closely related,
further more, Murphy’s model is a special case of Robins’s.
One of the most important advantages of these dynamic treatment regimes is the con-
sideration of treatment delayed effects to patients. An optimal rule provides information
not only on the best treatment choice from the beginning but also treatment choices that
maximize outcomes for a later time. The ascertainment of the optimal adaptive treatment
strategy is an optimization problem receiving attention by many researchers. Dynamic
programming combined with computational methodology is one of the most promising
approaches for finding optimal decisions. In particular, we will introduce in Chapter
3 reinforcement learning and its application to deal with this optimal individual-based
regime finding problem.
2.2 Optimal Controls for Drug Scheduling
2.2.1 Mathematical Models for Cancer Treatment
Modern treatment methods for cancer include improved traditional surgery, chemother-
apy and radiotherapy as well as immunotherapy. Modelling of the treatment process is
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viewed as a potentially powerful tool in the development of improving treatment reg-
imens. While biomedical research concentrates on the development of new drugs and
experimental (in vitro) and clinical (in vivo) determinations of their treatment sched-
ules, analysis of mathematical models can assist in testing various treatment strategies
and searching for optimal ones.
Mathematical models for cancer chemotherapy treatments have a long history and
have attracted extensive research over the past several decades. Several approaches to
modelling chemotherapeutic induced cell-kill (killing of tumor cells) have been developed.
One of the early approaches was by Schabel, Skipper, and Wilcox (1964) who proposed
that cell-kill due to a chemotherapeutic drug was proportional to the tumor population.
It states that for a fixed dose, the reduction of large tumors occurred more rapidly
than for smaller tumors. Skipper’s concept is referred to as the log-kill mechanism.
Mathematically, the general form of the model under investigation is depicted by the
differential equation:
N˙(t) = rN(t)F (N)−G(N(t), t),
where N is the tumor size, r is the growth rate of the tumor, F (N) is the generalized
growth function. For Skipper’s model, Gompertzian growth is applied:
F (N) = ln
(Θ
N
)
.
And the function G(N(t), t) is the cell kill term, describing the pharmacokinetic (PK)
and pharmacodynamic (PD) effects if the drug on the system. In Skipper’s log-kill (i.e.,
percentage kill) hypothesis,
G(N, t) = δu(t)N,
where δ is the magnitude of the dose and the control, and u(t) describes the time depen-
dent pharmacokinetics of the drug. In some diseases, for example, Hodgkin’s disease and
acute lymphoblastic leukemia, Norton, and Simon (1977; 1986) found Skipper’s model to
be inconsistent with clinical observations. The reduction in large tumors was slower than
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in histologically similar smaller tumors. Therefore, Norton and Simon hypothesize that
the cell-kill is proportional to the growth rate (e.g., exponential, logistic, or Gompertz)
of the tumor. In Norton-Simon’s hypothesis,
G(N, t) = δu(t)F (N).
A third hypothesis notes that some chemotherapeutic drugs must be metabolized by an
enzyme before being activated. This reaction is saturable due to the fixed amount of
enzyme. Thus, Holford, and Sheiner (1981) developed the Emax model which describes
cell-kill in terms of a saturable function of Michaelis-Menton form. In the Emax model,
G(N, t) =
δu(t)N
K +N
.
The model considered by Matveev and Savkin (2002) is a more complex one, wherein
the negative effects of the tumor cells on the healthy cell population are also considered.
This is a vital addition to the earlier three models which did not consider the interac-
tion between the tumor and the healthy cells. It should be noted that the healthy cell
population is also assumed to follow a Gompertz growth model with the cytotoxic drug
killing both the cancerous as well as normal cells. The set of differential equations for
this mathematical model is:
N˙(t) = αNln
θN
N
− L1(c)N
L˙(t) = βLln
θL
L
− L2(c)L− Ξ(N)L
c = c(t) ∈ [0, cmax],
where N(t) is the population of the tumor cells, L(t) is the population of the normal
(healthy) cells, θN is the maximum allowable size of the tumor, θL is the normal size of
the healthy cell population and c(t) (the control) is the concentration of the cytotoxic
drug at the tumor site. The inhibiting effect of the cancerous cells on the healthy cells
is captured by the −Ξ(N)L term. The function Ξ(·) is a strictly increasing function
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of N and is continuously differentiable on the interval [0,∞]. Some other theoretical
studies and mathematical works have been conducted to investigate cancer treatment.
For information on T cell sensitivity, see Chan, George, and Stark (2003). For more
related models, see Panetta and Kirschner (1998), Swan (1986; 1990), de Pillis and
Radunskaya (2001), and Murray (1990a; 1990b).
More recently, de Pillis et al. (2007a) investigated a mathematical model of tumor-
immune interactions with chemotherapy, and strategies for optimally administering treat-
ment. In their model, two immune components (effector-immune cells and circulating
lymphocytes) were included. They used the count of circulating lymphocytes in a pa-
tient’s bloodstream as a reflection of the strength of the patient’s overall immune health.
The system of differential equations describing the growth, death, and interactions of cell
populations with a chemotherapy treatment is given by
T˙ (t) = aT (1− bT )− c1NT −KTMT
N˙(t) = α1 − fN + g T
h+ T
N − pNT −KNMN
C˙(t) = α2 − βC −KCMC
M˙(t) = −γM + VM(t),
where T (t) is the tumor cell population, N(t) is the effector-immune cell population, C(t)
is the circulating lymphocyte population, and M(t) is the chemotherapy drug concentra-
tion.
In addition to chemotherapy, recently, immunotherapies are quickly becoming an
important component in the multi-pronged approaches being developed to treat certain
forms of cancer. Immunotherapy refers to the use of natural and synthetic substances
to stimulate the immune response. The goal of immunotherapy is to strengthen the
body’s own natural ability to combat cancer by enhancing the effectiveness of the immune
system. See, for example, Farrar et al. (1999), Morecki et al. (1996), Muller et al. (1998),
O’Byrne et al. (2000), and Stewart (1996). Immunological therapies include the use of
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antigen and nonantigen specific agents such as cytokins. Cytokines have been used to
treat melanoma, leukemia, lymphoma, neuroblastoma, Kaposi’s sarcoma, mesothelioma,
brain cancer, cancer of the kidney, and cancer of the cervix. Interleukin-2 (IL-2) is a
cytokine that was approved by the US Food and Drug Administration (FDA) in 1992
for treatment of metastatic renal cell (kidney) cancer. IL-2 helps immune system cells
reproduce more rapidly once they are in the patient, and it became the first cytokine
approved for use alone in treating advanced cancer. Clinical trials of mixed chemo-
immunotherapy are developed for metastatic melanoma treatment. For instance, a series
of sequential Phase II trials were conducted at M.D. Anderson Cancer Center (Buzaid
2000; Buzaid and Atkins 2001). These trials were based on integrating of IL-2 and
interferon-alpha (IFN-α) with the CVD (cisplatin, vinblastine, and dacarbazine) regimen.
One of the first attempts to consider effects of immunotherapy within an appropri-
ate mathematical model was made by Kirschner and Panetta (1998). de Pillis, Gu,
and Radunskaya (2006) proposed and analyzed a mathematical model governing cancer
growth on a cell population level with combination immunotherapy, chemotherapy and
vaccine treatment. This model’s characteristics are useful not only to gain a broad un-
derstanding of the specific system dynamics, but also to help guide the development of
combination therapies. The model describes the kinetics of four populations (tumor cells
and three types of immune cells), as well as two drug concentrations in the bloodstream,
using a series of coupled ordinary differential equations (ODEs) based on the model de-
veloped by de Pillis and Radunskaya (2003) in their previous study. The populations at
time t are denoted by:
• T (t), tumor cell population,
• N(t), total NK cell population,
• L(t), total CD8+T cell population,
• C(t), number of circulating lymphocytes (or white blood cells),
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• M(t), chemotherapy drug concentration in the bloodstream,
• I(t), immunotherapy drug concentration in the bloodstream.
Bringing together the specific forms for each cell growth and interaction term leads
to the full system of ODEs:
T˙ (t) = aT (1− bT )− cNT −DT −KT (1− e−M)T (2.1)
N˙(t) = eC − fN + g T
2
h+ T 2
N − pNT −KN(1− e−M)N (2.2)
L˙(t) =−mL+ j D
2T 2
k +D2T 2
L− qLT + (r1N + r2C)T
− uNL2 −KL(1− e−M)L+ pILI
gI + I
+ vL(t) (2.3)
C˙(t) = α− βC −KC(1− e−M)C (2.4)
M˙(t) = −γM + vM(t) (2.5)
I˙(t) = −µII + vI(t) (2.6)
D = d
(L/T )l
s+ (L/T )l
, (2.7)
where the time denoted functions vL(t), vM(t), and vI(t) are the drug intervention terms
for tumor infiltrating lymphocyte (TIL), chemotherapy drug, and interleukin-2 (IL-2),
respectively.
To obtain data which could mimic real-life clinical data, we will use time-domain
simulations of a nonlinear ODE model. In Section 4.2, we will provide more detailed
discussion for the main characteristics of our proposed model, before defining the data
generation procedure itself.
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2.2.2 Finding Optimal Treatment Solutions
Given a set of mathematical models (for example, ODEs), optimal control theory is one
of the mathematical optimization methods for deriving control policies. It was originally
introduced by Pontryagin et al. (1962) as a convenient method of finding a control law
for a given system such that a certain optimality criterion is achieved. A control problem
usually includes an objective functional that is a function of state and control variables.
The objective functional takes one or more functions as an argument and returns a
number.
There exists the inevitable trade-offs involved in cancer treatment because many anal-
yses show that large amounts of chemotherapy will kill the tumor, but it may also kill the
patient. In the context of mathematically modelling cancer growth with chemotherapy,
because of this implicit understanding that chemotherapy has damaging side effects, it
is common to frame an optimal control problem so that the total amount of drug is min-
imized (Matveev and Savkin 2002; Fister and Panetta 2003). It is appealing to use an
optimal control strategy to accomplish this, since the solution of it may cure the patient
as fast as possible with the minimized dose level.
A simple abstract framework goes as follows. Given a dynamical system with input
of IL-2 u1(t), input of chemotherapy u2(t), and the size of the tumor at the end of the
treatment period C(t), define an objective functional to be minimized. The objective
functional is the sum of the path costs, which usually take the form of an integral over
time, and the terminal costs, which is a function only of the terminal state, tf . Thus,
this objective functional typically takes the form
J(u1, u2) =
∫ t=tf
t=0
λ1u1(t) + λ2u2(t)dt+ C(tf ).
Here, finding the optimal treatment strategy is the equivalent of minimizing J .
In optimal control theory, establishing the existence of the solution is the first task.
Mathematically, using the fact that the solution to each state equation is bounded, the
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existence of an optimal control for many problems can be determined using the theories
developed by Fleming and Rishel (1975), Seierstad and Sydsaeter (1987), and Hartl et
al. (1995) (Filippov-Cesari’s theorem). Then, characterizing the optimal control can be
accomplished by using Pontryagin’s maximum principle (a necessary condition) (Pon-
tryagin et al., 1962), by solving the Hamilton-Jacobi-Bellman equation (a sufficient con-
dition), or by using other conditions from Kamien and Schwarz (1991) or the generalized
Legendre-Clebsch conditions (Krener, 1977).
Although optimal control theory is promising, in some situations finding the solution
can be very challenging. The optimal solution depends on the complexity of the mathe-
matical model, the objective functional and the state constraints. One disadvantage of
optimal control is its sensitivity to the choice of objective functionals. For instance, Fis-
ter and Donnelly (2005) demonstrated qualitatively different treatment strategies based
on the use of different objective functionals. These differences show the importance of
defining an objective functional that most accurately reflects the toxicities of a particular
drug along with the objective of the treatment strategy. Some objective functionals can
be theoretically analyzed more tractably than others. de Pillis et al. (2007a) provided
an example to illustrate this. In their study, they analyzed two types (quadratic and
linear controls) of objective functionals for the models of chemotherapy. In the quadratic
case, the control quickly moves to a small value, then gradually decreases, however in the
linear control it is essentially turned off (appears to be the so-called bang-bang control).
Since the amount of drug being delivered to the patient is small, the quadratic control
treatment is comparable to the linear bang-bang control case in that the tumor is reduced
by the same magnitude over the same time frame. Treatments based on both functionals
were successful in reducing the tumor. Although the quadratic and linear controls have
similar behavior in the administration of the chemotherapy drug, applying the control
in a linear fashion to their model is somewhat problematic. When dealing with linear
controls, singular representations are difficult to determine, and the possibility of a sin-
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gular control can not be ruled out. So in most situations, suitable objective functionals
need to be defined to capture the tumor cell population and the amount of drug used for
the therapy. It will be important to choose the correct functional and the appropriate
constraints since it is difficult to say exactly what these are before analyzing the model.
Another limitation of optimal control is that usually only the simple models with a
small number of variables can be analyzed theoretically. When the mathematical models
are very complex with a large number of variables and parameters, it is difficult to
seek optimal bang-bang solutions successfully. For example, see the model (2.1)–(2.7) of
mixed immuno-chemotherapy of tumor in de Pillis et al. (2006; 2007b). Although there
are conditions in which the controls exist singularly, and this may be the best strategy
for minimizing a tumor burden, the characterizations of the singular control can not be
explicitly determined in some settings.
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3 Reinforcement Learning, Q-Learning, and Their
Approximations
3.1 Introduction
Our goal in this chapter is to introduce the reinforcement learning theory, which will
be used to discover optimal therapies in clinical cancer trials. From a computer science
perspective, reinforcement learning is the first field to address the computational issues
that arise when learning from interaction with an environment in order to achieve long-
term goals (Sutton and Barto, 1998). Moreover, in contrast with adaptive design and
optimal control introduced in previous chapters, reinforcement learning (Q-learning) is a
model-free method which can be used for finding individualized therapies. This approach
we explore is much more focused on goal-directed learning from interaction with the
environment than other approaches to machine learning.
Multiple scientific fields have made contributions to reinforcement learning — ma-
chine learning, operations research, control theory, psychology, and neuroscience, to name
but a few. Reinforcement learning has been applied successfully in a number of area,
and has produced some successful practical applications. These applications range from
robotics and control to industrial manufacturing and combinatorial search problems such
as computer game playing (Kaelbling, Littman, and Moore, 1996). One example is that
reinforcement learning has been used to teach an autonomous controller to fly a helicopter
upside down (see Figure 1), demonstrating unequivocally the potential of reinforcement
learning for solving problems that are complex and counter-intuitive (Ng et al., 2006).
Another most convincing application is TD-gammon, a system that learns to play the
game of Backgammon by playing against itself and learning from the results, described
by Gerald Tesauro in (Tesauro, 1994; 2002). TD-gammon reaches a level of play that is
superior to even the best human players. Recently, there has been some interest in the
application of reinforcement learning algorithms to problems from the fields of manage-
ment science and operations research. In an interesting paper by Gosavi, Bandla, and
Das (2002), reinforcement learning is applied to airline yield management, and the aim
is to find an optimal policy for the denial/acceptance of booking requests for seats in
various fare classes. A second example is Crites and Barto (1998), where reinforcement
learning is used to find a (sub)optimal control policy for a group of elevators. In both
the above papers, the authors report that reinforcement learning based methods out-
perform the best and most often used standard algorithms. A marketing application is
described in Pednault, Abe, and Zadrozny (2002), where a target selection decision in
direct marketing is seen as a sequential problem.
This chapter is organized as follows. In Section 3.2, we describe the definition of
reinforcement learning in a simplified setting, one that does not involve multiple agents
to act in more than one situation. In Section 3.2.1, we show why the value function
(function of states or state-action pairs) is the unique solution to the Bellman equation.
The temporal-difference learning is introduced and discussed in Section 3.2.2. At the
end of Section 3.2.2, we take a step closer to the Q-learning problem, which is one of the
most important breakthroughs in reinforcement learning. In addition, in Section 3.3–3.5,
we discuss three recent flexible techniques from the machine learning literature, support
vector machines (SVM), support vector regression (SVR), and extremely randomized
trees (ERT), as our main methods to fit Q-functions and to learn an optimal policy using
a training data set.
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3.2 Reinforcement Learning and Q-Learning
Inspired by related psychological theory in computer science, reinforcement learning is a
sub-area of machine learning. A detailed account of the history of reinforcement learn-
ing is found in Sutton and Barto (1998). The basic process of reinforcement learning
involves trying a sequence of actions, recording the consequences of those actions, statis-
tically estimating the relationship between actions and consequences, and then choosing
the action that results in the most desirable consequence. In our reinforcement learning
design, the thing a patient interacts with is called the “environment”, which may indicate
the complex system consisting of the human body and more sources of error and greater
restrictions on what can be measured. While these interactions continually happen, we
choose a sequence of actions applied to the patient and the environment responds to
those actions and provides feedback. To be specific, we use S and A to denote random
variables, where S represents the set of environmental “states” and A represents the
set of possible “actions”. Here “states” may represent individual patient covariates and
“actions” can be denoted by various treatments or dose levels. Both variables can be
discrete or continuous. Define time-dependent variables St = {S0, S1, . . . , St}, and simi-
larly, define At = {A0, A1, . . . , At}. We use lower case letters, such as s and a, to denote
the realized values of the random variables S and A, respectively. Also, for convenience,
define st = {s0, s1, . . . , st}, and similarly, at = {a0, a1, . . . , at}. We assume the finite
longitudinal trajectories are sampled at random according to a distribution P . Such a
distribution is composed of the unknown distribution of each St conditional on previous
(St−1,At−1). We denote these unknown conditional densities as {f0, . . . , fT}, and denote
expectations with respect to the distribution P as E.
As a consequence of a patient’s treatment, after each time step t, the patient receives
a numerical reward rt. This could be denoted as a function, which maps to a single
number the key elements: previous state st, action at, and current state st+1. When
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t = 0, 1, . . . , T , this process can be described by
rt = R(st, at, st+1).
Reinforcement learning is learning what to do, how to map situations from state space
S to action space A, and depending on what our goal is, how to choose at to maximize
or minimize the expected discounted return:
Rt = rt + γrt+1 + γ
2rt+2 + · · ·+ γT rt+T =
T∑
k=0
γkrt+k.
In this equation, γ is the discount rate (0 ≤ γ ≤ 1), which means, rewards that are
received in the future are geometrically discounted according to γ. Additionally, we can
interpret γ in another way. It can be seen as a control to balance the agent’s immediate
rewards and future rewards. If γ = 0, we easily see that Rt = rt, and we only need to
learn how to choose at so as to maximize or minimize the immediate reward rt. As γ
approaches 1, we take future rewards into account more strongly. In the extreme case,
when γ = 1, we fully maximize or minimize rewards over the long run.
Another key element of a reinforcement learning system is an exploration “policy”,
p, which maps state st and action at−1 to the probability pt(a | st, at−1) (the probability
that action a is taken given history {st, at−1}). If the policy is possibly non-stationary
and non-Markovian but deterministic, we denote pit(st, at−1) = at. In other words, policy
pit as a step in a sequence of decision rules {pi1, . . . , piT} is an action. Let the distribution
Ppi denote the distribution of training data whereby the policy pi is used to generate
actions. Then we can denote expectations with respect to the distribution Ppi by an Epi.
Let Π be the collection of all policies, and expectation Epi ranges are over pi ∈ Π. For
simplicity and with no loss of generality, in our study, we mainly concentrate on the goal
of discovering which treatment yields a maximized reward for a patient. So seeking the
policy that maximizes the expectations with respect to the sum of the rewards over the
time trajectories is the ultimate goal of the study.
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3.2.1 Value Functions and the Bellman Equation
Efficiently estimating the value function is the most important component of almost all
reinforcement learning algorithms. The value function is defined as a function of a state
or state-action pair, and the function represents the total amount of reward an agent can
expect to accumulate over the future, starting from a given state. Recalling that Π is
the set of all policies, we define the value function V (s) to be the expected return when
starting in s under a policy pi ∈ Π. This is formally denoted as
V (s) = Epi
[
Rt | st = s
]
= Epi
[ T∑
k=0
γkrt+k | st = s
]
. (3.1)
We are more interested in defining the time-dependent value function for history (st, at−1),
that is,
Vt(st, at−1) = Epi
[ T∑
k=0
γkrt+k | St = st,At−1 = at−1
]
. (3.2)
Equation (3.1) and (3.2) are called the state-value functions for policy pi and the action-
value function for policy pi in Sutton and Barto (1998, page 69), respectively.
A fundamental property of value functions used throughout reinforcement learning is
that they satisfy particular recursive relationships. To see this, first let T =∞, then we
extend equation (3.2) as follows,
Vt(st, at−1) = Epi
[ ∞∑
k=0
γkrt+k | St = st,At−1 = at−1
]
= Epi
[
rt + γ
∞∑
k=0
γkrt+k+1 | St = st,At−1 = at−1
]
= Epi
[
rt + γVt+1(St+1,At) | St = st,At = at
]
=
∑
at
pit(st+1, at)
∑
s′
Pass′
[
Rass′ + γVt+1(s′)
]
,
where
Pass′ = Pr{st+1 = s′ | st = s, at = a}
and
Rass′ = E
[
rt | st = s, at = a, st+1 = s′
]
.
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The last two equations are two forms of the Bellman equations for Vt(st, at−1). The Bell-
man equation was first introduced by Bellman (1957). The Bellman equation expresses
the relationship between the value of a state and the values of its successor states: the
value of the start state is equivalent to the value of the expected next state plus the
expectation of the reward along the way. It is worth noting that the value function
Vt(st, at−1) is the unique solution to its Bellman equation.
Before we consider seek the best policy to maximize the reward, we describe the
optimal value function and optimal policy here first. The optimal value function is
simply defined as
V ∗t (st, at−1) = max
pi∈Π
Vt(st, at−1) = max
pi∈Π
Epi
[ T∑
k=0
γkrt+k | St = st,At−1 = at−1
]
.
The optimal policy is defined as a policy which yields the value function Vt(st, at−1) with
the highest value. Although there may be more than one, we denote all the optimal
policies by pi∗. Based on the existence of an optimal policy, we can establish the Bellman
optimality equation, which expresses the fact that the value of a state under an optimal
policy must equal the expected return for the best action from the state. Thus, the
Bellman optimality equation for V ∗t (st, at−1) is derived as follows:
V ∗t (st, at−1) = max
at
Epi∗
[ ∞∑
k=0
γkrt+k | St = st,At−1 = at−1
]
= max
at
Epi∗
[
rt + γ
∞∑
k=0
γkrt+k+1 | St = st,At−1 = at−1
]
= max
at
E
[
rt + γV
∗
t+1(St+1,At) | St = st,At = at
]
= max
at
∑
s′
Pass′
[
Rass′ + γV ∗t+1(s′)
]
.
It is clear that the optimal policy, pi∗, must satisfy
pi∗t (st, at−1) ∈ argmax
at
E
[
rt + γV
∗
t+1(St+1,At) | St = st,At = at
]
.
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Modern techniques in mathematical and computational areas have stimulated the
developments of many methods for estimating the optimal value functions or optimal
policies. Many of the existing methods can be categorized into one of the following
two classes: dynamic programming and temporal-difference learning (Sutton and Barto,
1998). Bellman (1957) first provided the “dynamic programming” term to show how
these methods are useful to a wide range of problems. Minsky (1961) first described the
connection between dynamic programming and reinforcement learning. In classical dy-
namic programming methods, “policy evaluation” and “policy improvement” (Bellman
1957; Howard 1960) refer to the computation of the value function and the improved
policy, respectively. The computation in both methods requires an iterative process.
Combining these two methods together, we obtain two other methods called “policy it-
eration” and “value iteration” (Puterman and Shin 1978; Bertsekas 1987). Although
dynamic programming can be applied to many types of problems, it is restricted to solv-
ing reinforcement learning problems under the Markov assumption. If this assumption
is violated, it may not be possible to find an exact solution. Additionally, dynamic pro-
gramming for solving reinforcement learning problems requires knowledge of a complete
and accurate model of the environment. Specifically, for instance, it requires Pass′ to
be fully observed. This may be unrealistic in the clinical trial setting because of the
heterogeneity in the model across individual patients.
In contrast, in reinforcement learning an agent does not necessarily know the reward
function and the state-transition function. Both the reward and the new state that result
from an action are determined by the environment, and the consequences of an action
must be observed by interacting with the environment. In other words, reinforcement
learning agents are not required to possess a model of their environment. This aspect
distinguishes reinforcement learning from dynamic programming. In the next section
we will discuss temporal-difference learning, which is a reinforcement learning algorithm
that does not need such a model to find an optimal policy in an MDP.
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3.2.2 Temporal-Difference Learning and Q-Learning
In the previous section we have defined optimal value functions and optimal policies, and
we have reviewed the Bellman optimality equation and dynamic programming methods
for obtaining an optimal policy based on the Markov property, assuming that we already
have a model of the environment. Actually, even if we have a complete and accurate
model of the environment’s dynamics, it is usually not possible to directly compute an
optimal policy by just solving the Bellman optimality equation. This section examines
model-free learning, that is, temporal-difference (TD) learning, which was first introduced
by Sutton (1988).
One fundamental expression of TD-learning is the incremental implementation. This
implementation requires less memory for estimates and less computation. The general
form is
new estimate← old estimate + stepsize
[
target− old estimate
]
.
Specifically, if we replace estimate with value function, target with reward function, and
denote stepsize as α, then in this case TD learning becomes
Vt(St,At−1)← Vt(St,At−1) + α
[
rt + γVt+1(St+1,At)− Vt(St,At−1)
]
. (3.3)
Roughly speaking, the TD method bases its incremental implementation in part on
an existing estimate. Recalling the Bellman equation in the previous section, we know
that
Vt(st, at−1) = Epi
[ ∞∑
k=0
γkrt+k | St = st,At−1 = at−1
]
= Epi
[
rt + γ
∞∑
k=0
γkrt+k+1 | St = st,At−1 = at−1
]
= Epi
[
rt + γVt+1(St+1,At) | St = st,At = at
]
.
In these equations, under a policy pi, each V represents the true value of a state-action
pair, but this is not known. Thus, in (3.3), the TD target uses the current estimate V
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instead of the true V . TD learning as discussed above is also known as TD(0) learning,
which is a special case of TD(λ) learning. Almost any TD(λ) learning belongs to the
“eligibility traces” problem. For more details on these issues, see Sutton and Barto (1998)
and Kaelbling, Littman, and Moore (1996).
One of the most important off-policy TD-learning methods is Watkins’ Q-learning
(Watkins, 1989; Watkins and Dayan, 1992). Q-learning handles discounted infinite-
horizon Markov decision process (MDP). It requires no prior knowledge, is exploration
insensitive and easy to implement, and is so far one of the most popular and seems to
be the most effective model-free algorithm for learning from delayed reinforcement. In
the situation where we don’t have any information about the transition function or the
probability distribution of the random variables, such a model-free method can be used
to find optimal strategies from the unknown system.
Q-learning no longer requires estimating the value function, it estimates a Q-function
instead. The algorithm therefore utilizes such a Q-function which calculates the quality
of a state-action combination as follows:
Q : S × A→ R.
The motivation of Q-learning is that once the Q functions have been estimated, we only
need to know the state to determine an action, without the knowledge of a transition
model that tells us what state we might go to next. Before learning has started, Q returns
a fixed value which is chosen by the designer. Then, at each time point t, the learner
is given a reward value which is calculated for each combination of a state st ∈ St, and
action at ∈ At. The core of the algorithm is a simple value iteration update. It assumes
the old value and makes a correction based on the new information as follows (Sutton
and Barto, 1998):
Qt(st, at)← Qt(st, at) + αt(st, at)×
[
rt + γmax
at+1
Qt+1(st+1, at+1)−Qt(st, at)
]
,
where rt is the current reward given at time t, αt(st, at) ∈ (0, 1] the learning rate (or
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learning step-size). αt(st, at) is a constant which determines to what extent the newly
acquired information will override the old information, that is, how fast learning takes
place. A factor of 0 will make the learner not learn anything, while a factor of 1 would
make the learner fully update based on the most recent information. We can interpret γ as
a control to balance a learners’ immediate rewards and future rewards. As γ approaches
1, we take future rewards into account more strongly. In the following context, we let
γ = 1, which means we fully maximize rewards over the long run. For simplicity of
computation, we ignore the step-size (let αt(st, at) = 1) for the rest of the article. All
results hold with minor modifications when the step-size effects are considered.
From a statistical perspective, the optimal time-dependent Q-function is
Q∗t (st, at) = E
[
rt + γV
∗
t+1(St+1) | St = st,At = at
]
.
Note that since
V ∗t (st) = max
at
Q∗t (st, at−1, at),
it is relatively easy to determine an optimal policy, which satisfies
pi∗t (st, at−1) = argmax
at
Q∗t (st, at−1, at).
One-step Q-learning has the simple recursive form
Qt(St,At)← rt + γmax
at+1
Qt+1(St+1,At, at+1). (3.4)
Under some appropriate and rigorous assumptions, Qt has been shown to converge to Q
∗
with probability 1 (Watkins and Dayan, 1992). More general convergence results were
proved by Jaakkola, Jordan, and Singh (1994) and Tsitsiklis (1994).
In learning a non-stationary non-Markovian policy with one set of finite horizon tra-
jectories (training data set)
{S0, A0, r0, S1, A1, r1, . . . , AT , rT , ST+1},
we denote the estimator of the optimal Q-functions based on this training data by Q̂t,
where t = 0, 1, . . . , T . According to the recursive form of Q-learning in (3.4), we must
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estimate Qt backwards through time t = T, T − 1, . . . , 1, 0, that is, estimate QT from the
last time point back to Q0 at the beginning of the trajectories. And we set QT+1 equal
to 0 in the first equation, yielding
QT (ST ,AT )← rT + γmax
aT+1
QT+1(ST+1,AT , aT+1).
In order to estimate each Qt, we denote Qt(st, at; θ) as a function of a set of parameters
θ, and we allow the estimator to have different parameter sets for different time points t.
Once this backwards estimation process is done, we save the sequence {Q̂0, Q̂1, . . . , Q̂T}
for estimating optimal policies,
pit = argmax
at
Q̂t(st, at; θt),
where t = 0, 1, . . . , T , and thereafter use these optimal policies to test or predict for a
new data set.
There are many other promising learning methods based on modification or extension
of Q-learning, for example, Blatt, Murphy, and Zhu (2004) proposed A-learning. How-
ever, some properties of these methods have not yet been carefully investigated. Due
to the simple equation expressions and the minimal amount of computation, we restrict
our attention to Q-learning for discovering effective therapeutic regimens in our clinical
settings.
3.3 Support Vector Machines (SVM)
As we mentioned earlier in Chapter 2, either adaptive design or optimal control must
proceed by using explicit mathematical models. This requirement yields a limitation for
discovering optimal dynamic treatment regimens that are tailored to individual patient
needs. Thus we introduced a powerful technique from computer science and statistics
— reinforcement learning, specifically Q-learning — to our clinical trial design setting.
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Q-learning could circumvent this situation by its emphasis on learning through the indi-
vidual’s interaction with its environment, without relying on any complete models of the
environment. We call this application to clinical trial design as “Reinforcement Learning
Design” or “Q-learning Design”.
In Section 3.3–3.5, our main aim is to estimate the Q-function for finding the cor-
responding optimal policy. However, challenges may arise due to the complexity of the
structure of true Q-function, including the high-dimension of the states variable S, the
high-dimension of the action variable A, or when the action space is continuous. In order
to obtain the estimator of interest, many authors consider different approaches in re-
cent years. Murphy (2005b), Blatt, Murphy, and Zhu (2004) and Tsitsiklis and van Roy
(1996) showed that Q-learning estimating can be viewed as approximating least squares
value iteration. The parameters θt for the t-th Q-function satisfy
θt ∈ argmin
θ
En
[
rt + max
at+1
Qt+1(St+1,At, at+1; θt+1)−Qt(St,At; θ)
]2
.
This is consistent with the one-step update of Sutton and Barto (1998) with γ = 1,
and furthermore, it is generalized to permit function approximation and non-stationary
Q-functions. Another simple and standard estimating form is in Murphy et al.’s (2007)
method. They claimed that Q-learning is a generalization of the familiar regression
model. In their sequential multiple assignment randomized trial (SMART) design, there
are only two treatment decisions. Thus construction of the decision rules should be
addressed from the second decision to the first decision (backwards). For instance, in
the second decision, two treatment options are available. If we denote A2 as the second
decision, it is coded as 1 if the switch is assigned and is coded as 0 if augmentation is
assigned. Based on the SMART data, the regression model for Q2 is
Q2(S,A2; θ) = β0 + β1S + (β2 + β3S)A2,
where θ = (β0, β1, β2, β3) and S indicates the state value (a summary of side effects) up to
the end of the first decision point. When the dimension of actions is low, linear regression
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methods should be adequate, but in more extreme cases these methods can be question-
able. Considering the one possible set {a0, a1, . . . , an} with n ≥ 3, the linear regression
method may only yield the optimal decision as a0 or an due to the maxaQ(S,A, a; θ)
term in the Q-learning implementation, therefore, quadratic regression or higher order
polynomial regression may be desired for estimating the Q-function. The complex and
unclear structure of the Q-function has motivated the vast literature on nonparametric
machine learning and statistical methods.
In this section, we introduce support vector machines (SVMs) as our main technique
for fitting Q-functions. The foundation of SVMs was developed by Vapnik (1995). SVMs
have received increasing attention from the statistical community as well as from com-
puter science and engineering, and they keep gaining popularity due to many attractive
features and promising empirical performance. The SVM paradigm is originally designed
for the classification problem, and it provides a compromise between the parametric and
the nonparametric approaches. SVMs are often involved in the solution of learning the
relationship between the x and y variables in a training data set {(xi,yi) ∈ X×Y }ni=1. In
Q-learning, the variable X may be replaced by {S,A} that represents states and actions
information, and Y may be replaced by r that represents numerical rewards. In this
section, we first illustrate the basic ideas of SVM for the typical two-group classification
problem. Then we briefly discuss support vector regression (SVR) as an extension of
SVM in Section 3.4.
The classification problems solved by SVMs can be restricted to consideration of
the two-class problem without loss of generality. A classification task usually involves
training and testing data which consist of some data instances. Each instance in the
training set contains one “class label” (y) and several “attributes” (x). SVM is used as
a statistical technique for classifying samples {(Φ(xi), yi) ∈ X × Y }ni=1, where yi = +1
or yi = −1 indicates the two possible classes, and Φ is a function mapping the attributes
xi into a “feature space”. This nonlinear transformation Φ guarantees that any data set
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becomes arbitrarily separable as the data dimension grows (Cover 1965).
Denoting wTΦ(x) + b = 0 as any separating hyperplane in the feature space, we can
rescale w and b so that the following equations hold for i = 1, . . . , n:
wTΦ(xi) + b
 ≥ 1, if yi = +1≤ −1, if yi = −1.
The distance between two classes 2/‖w‖ is called the margin. SVM works, roughly,
by finding the hyperplane in the feature space which separates the yi = +1 class from
the yi = −1 class with the largest margins. If the mapped data have become linearly
separable, the following equation has to be solved by maximizing the margin:
min
w,b
‖w‖2
subject to yi(w
TΦ(xi) + b) ≥ 1, i = 1, . . . , n. (3.5)
Consider the solution of equation (3.5), and denote it by w∗ and b∗. Points Φ(xi) that
satisfy
yi
[
(w∗)TΦ(xi) + b∗
]
= 1
are called support vectors (a sparse solution). As seen in Figure 2, SVMs calculate a
linear hyperplane by looking for margin maximation, so the solution only depends on
the support vectors (Cortes and Vapnik 1995). Usually support vectors just represent
a small fraction of the sample, therefore, this fact implies that, the evaluation of the
decision function D∗(x) = (w∗)TΦ(xi) + b∗ is computationally efficient. This attractive
property is especially useful when dealing with data sets with a low ratio of sample size to
dimension (for example, microarray data analysis). SVMs take advantage of this sparsity
in the data and are effective even for problems where the data is of dimensionality as
large as the number of samples.
A positive definite function, K(x1,x2) =
∑∞
i=1 λiΦi(x1)
TΦi(x2) called the kernel
(Mercer 1909), plays an important role in SVMs. If we restrict f(x) = wTΦ(x) to
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belong to a reproducing kernel Hilbert space (RKHS), then these functions can be ex-
pressed in an alternative form f(x) =
∑
j αjK(xj,x), with w replaced by
∑
j αjΦ(xj).
As a result, the knowledge of the explicit mapping Φ and the vector w is not needed,
we need only know the kernel K in its close form. Some basic examples of kernels (with
some kernel parameters) are:
1. Linear kernel K(x,y) = xTy: the mapping is the identity.
2. Polynomial kernel K(x,y) = (γxTy + c)d, γ > 0: which maps the data into a finite
dimensional vector space.
3. Gaussian kernel or Radial Basis Function (RBF) K(x,y) = exp(−γ‖x − y‖2):
which maps the data into an infinite dimensional space.
4. Sigmoid kernel K(x,y) = tanh(γxTy + c): which is a multi-layer perceptron.
We now consider the more general case where the mapped data remain nonseparable.
Let L indicate a loss function, then SVMs address this nonseparability problem by finding
a function f that minimizes an empirical error of the form
∑n
i=1 L(f(xi), yi). The specific
loss function is called hinge loss (Figure 3), defined as
L(f(xi), yi) = (1− yif(xi))+, (3.6)
with (x)+ = max(x, 0). Many authors (Ivanov 1976; Phillips 1962; Tikhonov and Arsenin
1977) express the search for a max-margin classifier as a convex optimization problem that
maximizes the margin between the data points with a hinge loss penalization for miss-
classified or almost miss-classified data points. The most widely used setting minimizes
Tikhonov’s regularization functional, which consists of solving the optimization problem:
min
f∈HK
1
n
n∑
i=1
(1− yif(xi))+ + µ‖f‖2K , (3.7)
where µ > 0 controls the trade-off between the fit of the solution f to the data (measured
by L) and the approximation capacity of the function space that f belongs to (measured
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by ‖f‖K). Based on the work of Kimeldorf and Wahba (1970), it is easy to show that
(3.7) can be restated as
min
w,b
1
n
n∑
i=1
(1− yi(wTΦ(xi) + b)+ + µ‖w‖2. (3.8)
In order to avoid the nondifferentiable problem due to the hinge loss function in (3.6),
Lin et al. (2002) demonstrated that solving problem (3.8) is equivalent to solving
min
w,b,ξ
1
2
‖w‖2 + C
n∑
i=1
ξi
subject to yi(w
TΦ(xi) + b) ≥ 1− ξi,
ξi ≥ 0, i = 1, . . . , n, (3.9)
where ξi are called slack variables and C = 1/2µn. Although (3.9) is the most widely used
SVM formulation, in practice, it is usually changed to a standard optimization problem
(convex and quadratic) equipped with Lagrange multipliers (λi):
min
λ
1
2
n∑
i=1
n∑
j=1
λiλjyiyjK(xi,xj)−
n∑
i=1
λi
subject to
n∑
i=1
yiλi = 0,
0 ≤ λi ≤ C, i = 1, . . . , n.
In conclusion, SVMs operate within the framework of regularization theory by min-
imizing an empirical risk. SVMs are consistent (with good asymptotic properties), and
their empirical error converges to the expected error, and under some conditions, con-
verges to the Bayes optimal rule. A significant advantage of the SVM is that sparse
solutions to classification problems are usually obtained. This fact facilitates the appli-
cation of SVMs to problems that involve data with high dimensional attributes.
In Q-learning, we define attributes xit ∈ St × At, i = 1, . . . , n, t = 0, . . . , T , where
St = {S0, S1, . . . , St} and At = {A0, A1, . . . , At}, and we assign the label index yit to each
reward value rit. In many cases the reward function maps (st, at, st+1) to a set which
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consists of some discrete integer number, and if the size of the set is larger than 2, it
is a multicategory classification problem. These kind of problems are often treated as
a sequence of binary classifications. For example, the “one versus rest” approach solves
k binary problems through sequential training. But this method may be suboptimal
and may yield poor performance due to the absence of a dominating class (Lee, Lin
and Wahba 2004). Liu and Shen (2006) proposed a novel multicategory ψ-learning to
treat all classes simultaneously. ψ-learning can deliver accurate multi-class prediction
and outperform its SVM counterpart. Other multi-class classification methods can be
found in Crammer and Singer (2001; 2003) and Lee, Lin and Wahba (2004). However,
when the number of the classes is large (more than 4) or in the extreme case where rt is
continuous, and the numerical value is not only the label index but it has meaning, then
the multicategory learning methods mentioned above may not be adequate. Therefore,
support vector regression (SVR), one of the most popular extensions of SVM, is motivated
and discussed in the next section.
3.4 Support Vector Regression (SVR)
SVMs were developed to solve the classification problem, but recently they have been
extended to the domain of regression problems (Vapnik, Golowich, and Smola 1997).
From a mathematical perspective, the support vector regression function is also derived
within the RKHS context. In contrast with SVM, one of the popular loss functions
involved in SVR is known as the -insensitive loss function (Figure 4), which is defined
as
L(f(xi), yi) = (|f(xi)− yi| − )+,
where  > 0 (Vapnik, 1995). That is, as long as the absolute difference between the actual
and the predicted values is less than , the empirical loss is zero, otherwise there is a cost
which grows linearly. SVR is more general and flexible than least-square regression, since
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it allows a predicted function that has at most  deviation from the actually obtained
targets yi for all the training data. Other possible loss functions include quadratic loss,
Laplace loss, and Huber loss. Similar to equation (3.7), by using the -insensitive loss
function, the following optimization problem arises:
min
f∈HK
1
n
n∑
i=1
(|f(xi)− yi| − )+ + µ‖f‖2K . (3.10)
Once more, similar to (3.8), problem (3.10) can be restated as
min
w,b
1
n
n∑
i=1
(|wTΦ(xi) + b− yi| − )+ + µ‖w‖2. (3.11)
Since the -insensitive loss function is also nondifferentiable, (3.11) can be solved by
appropriate optimization methods, that is,
min
w,b,ξ,ξ′
1
2
‖w‖2 + C
n∑
i=1
(ξi + ξ
′
i),
subject to (wTΦ(xi) + b)− yi ≤ + ξi,
yi − (wTΦ(xi) + b) ≤ + ξ′i,
ξi, ξ
′
i ≥ 0, i = 1, . . . , n. (3.12)
In practice, the following dual convex quadratic formulation with Lagrange multipliers
(λi) is used:
min
λ,λ′
1
2
(λ− λ′)TK(xi,xj)(λ− λ′)−
n∑
i=1
(yi − )λ′i +
n∑
i=1
(yi + )λi,
subject to
n∑
i=1
(λi − λ′i) = 0,
0 ≤ λi, λ′i ≤ C, i = 1, . . . , n. (3.13)
The ideas underlying SVR are similar but slightly differ from those within the margin-
based classification scheme. In -insensitive SVR (3.12), the slack variables ξi and ξ
′
i allow
for some data points in the feature space to stay outside the confidence band determined
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by . In other words, the goal is to find a function that has at most  deviation from the
actually obtained targets yi for all the training data. Errors with deviation larger than 
are not accepted. Once the above formulation is solved to get the optimal λi and λ
′
i, the
approximation function at x is given by:
f(x) =
n∑
i=1
(λ′i − λi)K(xi,x) + b. (3.14)
There are several examples where SVR are successfully used in practice, and they
perform better than other classification methods. See Chen, Chang, and Lin (2001)
and Smola and Scholkopf (2004). To achieve good performance by using SVM/SVR,
some procedures such as data scaling, kernel and related parameter selection need to be
examined very carefully. We discuss those procedures in detail in our simulation example
in Section 4.2.
3.5 Extremely Randomized Trees (ERT)
The complex and unclear structure of the Q-function has also partly motivated the vast
literature on nonparametric statistical methods and machine learning. Ernst, Geurts,
and Wehenkel (2005) and Geurts, Ernst, and Wehenkel (2006) proposed an extremely
randomized trees (ERT) method, which is called the Extra-Trees algorithm, for batch
mode reinforcement learning. Unlike classical classification and regression trees such as
Kd-tree or pruned CART tree, this nonparametric method builds a model in the form of
the average prediction of an ensemble of regression trees (called a random forest). More-
over, each tree built by this algorithm consists of strongly randomizing both attribute
and cut-point choice while splitting a tree node. In addition to the number of trees G,
this method depends on one parameter, called K, the maximum number of cut-direction
tests at each node, and nmin, the minimum number of elements at each leaf required to
split a node. The choice of an appropriate value of G depends on the resulting compro-
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mise between computational requirements and prediction accuracy. K determines the
strength of the randomization, for K = 1, the splits are chosen totally independent of the
output variable. A larger nmin yields smaller trees but higher bias. The ERT algorithm
builds G trees using the training data set. To determine a test at a node for each tree,
this algorithm randomly selects K attributes with K randomized cut-points. A score
is calculated for each test and then the one which has the highest value is kept. The
algorithm stops splitting a node when the number of elements in the node is less than
nmin. The complete ERT algorithm is given in Figure 5.
Compared to standard tree-based regression methods, ERT successfully leads to sig-
nificant improvements in precision. Additionally, it can dramatically decrease variance
while at the same time decreasing bias, and it is very robust to outliers. ERT has been
recently demonstrated in a simulation of HIV infection (Ernst et al., 2006) and adaptive
treatment of Epilepsy (Guez et al., 2008). While this algorithm reveals itself to be very
effective to extract a well-fitted Q from the data set, it has one drawback: the computa-
tional efficiency is relatively low especially with increasing sample size of patients in the
training data set.
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Figure 1: Helicopter in autonomous sustained hover (Ng et al., 2006).
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Figure 2: Linear separating hyperplane, margin, and support vectors defined in Support
Vector Machines (SVM).
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FIG. 2. (a) Nonseparable mapped data in the feature space. (b) Normalized hyperplane for the data in (a).
how SVMs make the problem well-posed. As a conse-
quence, the decision function calculated by the SVM
will be unique, and the solution will depend continu-
ously on the data.
The speciﬁc loss function L used within the SVM
approach is L(yi, f (xi )) = (1 − yif (xi ))+, with
(x)+ = max(x,0). This loss function is called hinge
loss and is represented in Figure 3. It is zero for well
classiﬁed points with |f (xi )| ≥ 1 and is linear other-
wise. Hence, the hinge loss function does not penalize
large values of f (xi ) with the same sign as yi (under-
standing large to mean |f (xi )| ≥ 1).
This behavior agrees with the fact that in classiﬁ-
cation problems only an estimate of the classiﬁcation
boundary is needed. As a consequence, we only take
into account points such that L(yi, f (xi )) > 0 to deter-
mine the decision function.
To reach well-posedness, SVMs make use of regu-
larization theory, for which several similar approaches
have been proposed [33, 60, 73]. The widest used
setting minimizes Tikhonov’s regularization function-
al [73], which consists of solving the optimization
problem
min
f∈HK
1
n
n∑
i=1
(
1 − yif (xi ))+ + μ‖f ‖2K,(3.1)
where μ > 0, HK is the RKHS associated with the
kernel K , ‖f ‖K denotes the norm of f in the RKHS
and xi are the sample data points. Given that f be-
longs to HK , it takes the form f (·) =∑j αjK(xj , ·).
As in Section 2, f (x) = 0 is a hyperplane in the fea-
ture space. Using the reproducing property 〈K(xj , ·),
K(xl , ·)〉K = K(xj ,xl) (see [3]), it holds that ‖f ‖2K =〈f,f 〉K =∑j
∑
l αjαlK(xj ,xl).
In (3.1) the scalar μ controls the trade-off between
the ﬁt of the solution f to the data (measured by L) and
the approximation capacity of the function space that f
belongs to (measured by ‖f ‖K ). It can be shown [11,
FIG. 3. Hinge loss function L(yi, f (xi )) = (1 − yif (xi ))+: (a) L(−1, f (xi )); (b) L(+1, f (xi )).
Figure 3: Hinge loss function L(f(xi), yi) = (1− yif(xi))+. In (a), L(f(xi),−1); in (b),
L(g(xi),+1).
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other classiﬁcation methods and in their worst case,
SVM performance is at least similar to the best non-
SVM method. For instance, in protein subcellular
location prediction [31], we have to predict pro-
tein subcellular positions from prokaryotic sequences.
There are three possible location categories: cyto-
plasmic, periplasmic and extracellular. From a pure
classiﬁcation point of view, the problem reduces to
classifying 20-dimensional vectors into three (highly
unbalanced) classes. Prediction accuracy for SVMs
(with a Gaussian kernel) amounts to 91.4%, while
neural networks and a ﬁrst-order Markov chain [75]
have accuracy of 81% and 89.1%, respectively. The re-
sults obtained are similar for the other problems. It is
important to note that there is still room for improve-
ment.
Regarding image processing, we will overview two
well-known problems: handwritten digit identiﬁcation
and face recognition. With respect to the ﬁrst problem,
the U.S. Postal Service data base contains 9298 sam-
ples of digits obtained from real-life zip codes (divided
into 7291 training samples and 2007 samples for test-
ing). Each digit is represented by a 16 × 16 gray level
matrix; therefore each data point is represented by a
vector in R256. The human classiﬁcation error for this
problem is known to be 2.5% [22]. The error rate for
a standard SVM with a third degree polynomial kernel
is 4% (see [22] and references therein), while the best
known alternative method, the specialized neural net-
work LeNet1 [39], achieves an error rate of 5%. For
this problem, using a specialized SVM with a third
degree polynomial kernel [22] lowers the error rate
to 3.2%—close to the human performance. The key to
this specialization lies in the construction of the deci-
sion function in three phases: in the ﬁrst phase, a SVM
is trained and the support vectors are obtained; in the
second phase, new data points are generated by trans-
forming these support vectors under some groups of
transformations, rotations and translations. In the third
phase, the ﬁnal decision hyperplane is built by training
a SVM with the new points.
Concerning face recognition, gender detection has
been analyzed by Moghaddam and Yang [45]. The data
contain 1755 face images (1044 males and 711 fe-
males), and the overall error rate for a SVM with a
Gaussian kernel is 3.2% (2.1% for males and 4.8%
for females). The results for a radial basis neural net-
work [63], a quadratic classiﬁer and FLDA are, respec-
tively, 7.6%, 10.4% and 12.9%.
Another outstanding application of SVMs is the de-
tection of human faces in gray-level images [56]. The
problem is to determine in an image the location of
human faces and, if there are any, return an encoding
of their position. The detection rate for a SVM using
a second degree polynomial kernel is 97.1%, while for
the best competing system the rate is 94.6%. A number
of impressive photographs that show the effectiveness
of this application for face location can be consulted
in [57].
5. EXTENSIONS OF SVMS: SUPPORT
VECTOR REGRESSION
It is natural to contemplate how to extend the kernel
mapping explained in Section 2 to well-known tech-
niques for data analysis such as principal component
analysis, Fisher linear discriminant analysis and clus-
ter analysis. In this section we will describe support
vector regression, one of the most popular extensions
of support vector methods, and give some references
regarding other extensions.
The ideas underlying support vector regression are
similar to those within the classiﬁcation scheme. From
an intuitive viewpoint, the data are mapped into a fea-
ture space and then a hyperplane is ﬁtted to the mapped
data. From a mathematical perspective, the support
vector regression function is also derived within the
RKHS context. In this case, the loss function involved
is known as the ε-insensitive loss function (see [76]),
which is deﬁned as L(yi, f (xi )) = (|f (xi )−yi |−ε)+,
ε ≥ 0. This loss function ignores errors of size less
than ε (see Figure 6). A discussion of the relation-
ship of the ε-insensitive loss function and the ones
used in robust statistics can be found in [28]. Using
this loss function, the following optimization problem,
similar to (3.1) (also consisting of the minimization of
FIG. 6. The ε-insensitive loss function L(yi, f (xi )) =
(|f (xi ) − yi | − ε)+, ε > 0.Figure 4: -insensitive loss function L(f(xi), yi) = (|f(xi)− yi| − )+.
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Build a tree(T S )
Input: a training set T S
Output: a tree T ;
• If
(i) #T S < nmin, or
(ii) all input variables are constant in T S , or
(iii) the output variable is constant over the T S ,
return a leaf labeled by the average value 1#T S ∑l ol .
• Otherwise:
1. Let [i j < t j] = Find a test(T S).
2. Split T S into T S l and T S r according to the test [i j < t].
3. Build Tl = Build a tree(T S l) and Tr = Build a tree(T S r) from these subsets;
4. Create a node with the test [i j < t j], attach Tl and Tr as left and right subtrees of this
node and return the resulting tree.
Find a test(T S )
Input: a training set T S
Output: a test [i j < t j]:
1. Select K inputs,{i1, ..., iK}, at random, without replacement, among all (non constant) input
variables.
2. For k going from 1 to K:
(a) Compute the maximal and minimal value of ik in T S , denoted respectively iT Sk,min and
iT Sk,max.
(b) Draw a discretization threshold tk uniformly in ]iT Sk,min, iT Sk,max]
(c) Compute the score Sk = Score([ik < tk],T S)
3. Return a test [i j < t j] such that S j = maxk=1,...,K Sk.
Figure 26: Procedure used by the Extra-Trees algorithm to build a tree. The Totally Randomized
Trees algorithm is obtained from this algorithm by setting K = 1 and by dropping the
stopping condition (iii).
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Figure 5: Complete algorithm used by extremely randomized trees (ERT) to build a
random forest (Geurts et al., 2006). T S denotes training set, (il, ol) denotes input-output
pair.
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4 Reinforcement Learning Treatment Strategies for
A Virtual Cancer Trial
4.1 Clinical Reinforcement Trials
In the previous chapter, we introduced reinforcement learning to cancer clinical trials.
The main advantage offered by using reinforcement learning in clinical trials is that
discovery is included in the trial itself, not just evaluation as is the case for standard
Phase III clinical trials. There are a number of ways this discovery occurs, but one of the
key ways is by the manner in which patient differences are leveraged to enable discovery
of effective treatments missed by standard clinical trial designs. Suppose, for example,
we have two drugs, A and B, and a continuous biomarker X which varies from patient to
patient. Suppose also that when X is less than or equal to its median value M , treatment
A is twice as effective as treatment B; but that when X is greater than M , treatment
A is half as effective as treatment B (i.e., it is harmful). In a standard randomize trial,
the benefit of treatment A would be washed out and completely undetected. However, if
we leveraged individual differences, we would find out that treatment A is very effective
when given to people for whom X ≤M but not given when X > M . Thus the proposed
approach is not just a nuanced improvement over standard clinical trials but a paradigm
shift in methods for discovering effective treatments.
In this section, we propose a new design and analysis method for a new kind of
clinical trial for life threatening diseases, “clinical reinforcement trials”. The design for
these trials consists of three aspects:
First, a finite, reasonably small set of decision times is identified. These times could
be either specific time points measured from trial onset or decision points in the treat-
ment process such as the starting times of a each new line of cancer treatment. For
example, in the simulation study below, we create a synthetic cancer treatment setting
where patients are monitored monthly for six months and treatment for each month is
determined based on patient biomarker values available at the beginning of the month.
As a second example, in NSCLC, it may be more appropriate to have one decision time
at the beginning of the first line of treatment, a second decision time at the beginning of
the second line of treatment, and possibly a third decision time at the beginning of the
third line of treatment. The third line is currently only available for certain patients and
there is only one FDA approved third line treatment, and so decision possibilities are
severely limited at the third decision time. Note that the decision time in this instance is
really a stage of treatment and not a calendar time. Other decision time sets, including
hybrid variants of the previous two examples, are also possible.
Second, for each decision time, a set of possible treatments to be randomized is
identified. The choice of treatments can be a continuum as mentioned earlier or a finite
set and can include restrictions which may be functions of observed variables such as
biomarkers. For example, in our simulations we restrict the dose of chemotherapy at
the first decision time to be above a threshold so that all patients are guaranteed some
initial treatment. When the set of treatments is finite, the proposed design reduces to a
SMART design.
Third, a utility function is identified which can be assessed at each time point and
which contains an appropriately weighted combination of outcomes available at each
interval between decision times and at the end of the final treatment interval. In our
simulation study below, we use a combination of tumor size and overall patient health
as our utility function.
Once the design has been determined, patients are then recruited into the study
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and randomized to the treatment set under the protocol restrictions at each decision
point, outcome measures used to compute patient state and utility are obtained, and
each patient is followed through to completion of the protocol or until the end of the
trial. The patient data is collected and Q-learning is applied, in combination with either
SVR or ERT applied at each time point as described above, to estimate the optimal
treatment rule as a function of patient variables and biomarkers, at each decision time.
We allow the Q-functions to differ from decision time to decision time. We will show
in the simulation study below that our proposed approach is able to generate treatment
rules that lead to improved patient outcomes. One open question which we will pursue
in a later paper is sample size guidelines. Fortunately, it appears from our simulation
studies that the sample sizes required are similar to and not larger than the sizes required
for typical phase III trials.
4.2 A Virtual Clinical Reinforcement Trial
In this section we simulate a sequentially randomized clinical reinforcement trial as a
numerical example to examine the performance of the proposed design and methodol-
ogy. To demonstrate that the optimal therapy found using Q-learning is superior to any
other regimens, the treatments at each course are specified in terms of a continuum of
dose levels of a single drug, and the comparisons we consider are between the optimal
regimen identified from our proposed clinical reinforcement trial procedure and various
constant-dose regimens. We first present a simple mathematical model for disease and
chemotherapy which we will be using for our study. We then present the specific im-
plementation of Q-learning which we will use for the simulation. This section concludes
with a presentation of the results of the simulation study.
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4.2.1 A Simple Chemotherapy Mathematical Model
As discussed in Section 2.2.1, there exists a large volume of literature concerning math-
ematical models of chemotherapy. To construct a set of training data reflecting a hy-
pothetical cancer trial, we need a simple chemotherapy mathematical model capable
of describing the fundamental principles governing tumor progression and responses to
therapy. The goal for a chemotherapy mathematical model is to allow for sufficient com-
plexity so that the model will qualitatively generate clinically observed in vivo tumor
growth patterns, while simultaneously maintaining sufficient simplicity to admit analy-
sis. Thus, inspired by discussions in Section 2.2.1, a sophisticated model we present must
exhibit: (1) tumor growth in the absence of chemotherapy; (2) patients’ negative wellness
outcomes in response to chemotherapy; (3) the drug’s capability for killing tumor cells
while also increasing toxicity; (4) an interaction between tumor cells and patient well-
ness. To obtain data which satisfy these requirements, we propose a system of ordinary
difference equations (ODE) modeled as follows:
W˙t = a1(Mt ∨M0) + b1(Dt − d1),
M˙t =
[
a2(Wt ∨W0)− b2(Dt − d2)
]
× 1{Mt > 0}, (4.1)
where time (with month as unit) t = 0, 1, . . . , T − 1. Note that these changing rates
yield a piecewise linear model over time. Without loss of trade-off between toxicity and
efficacy, the piecewise linear model can be implemented very easily. For simplicity, we
here consider tumor size instead of number of tumor cells. Mt denotes the tumor size
at the specified time, M0 indicates the value of tumor size when the patient is at the
beginning of the study. Wt measures the negative part of wellness (toxicity), similarly, W0
indicates the initial value of patient’s wellness. Dt denotes the chemotherapy drug level.
The value of other different parameters for the model are fixed as: a1 = 0.1, a2 = 0.15,
b1 = 1.2, b2 = 1.2, d1 = 0.5 and d2 = 0.5. The indicator function term 1{Mt > 0} in
(4.1) represents the feature that when tumor size is absorbed to 0, the patient has been
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cured, and there is no future recurrence of the tumor. Note that this model is not meant
to reflect a specific cancer but to reflect a generic plausible cancer created for illustration.
Before generating simulated clinical data, it is easy to notice that the dynamic model
has two state variables (Wt, Mt) and one action (treatment) variable (Dt). The state
variables can be obtained via:
Wt+1 = Wt + W˙t,
Mt+1 = Mt + M˙t,
where t = 0, 1, . . . , T − 1 are the T decision times we will utilize in our simulated trial
design. We generate a simulated clinical reinforcement trial with N = 1000 patients
(replicates) with each simulated patient experiencing 6 months (T = 6) of treatment
based on this ODE model. The initial values W0 and M0 for each patient are gener-
ated from independent uniform (0, 2) deviates. The treatment set consists of doses of a
chemotherapy agent with acceptable dose range of [0, 1], where the value 1 corresponds
to the maximum acceptable dose. The values chosen for chemotherapy drug level D0 are
simulated from the uniform (0.5, 1) distribution, moreover, D1, . . . , D5 are drawn accord-
ing to a uniform distribution in the interval (0, 1). Thus our treatment set is restricted
differently at decision time t = 0 than at other decision times to reflect a requirement
that patients receive at least some drug at onset of treatment. Various other distribu-
tion settings for the action space are possible, and clinical researchers have tremendous
flexibility when designing clinical reinforcement trials.
Figure 6 provides a disease progression example of one patient to show dynamic treat-
ment results with influence of different levels of chemotherapy drug. The system is clearly
sensitive to the chemotherapy dosing regimen. Note that when the dose level switches
to low, the tumor size grows to a dangerous level. Moreover, the toxicity increases (de-
creases) once the dosage is changed to a higher (lower) level. By applying reinforcement
learning to this crude computer model, we aim at uncovering the ideal regimen which
has the best trade-off between efficacy and toxicity.
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4.2.2 Q-function Estimation and Optimal Regimen Discovery
We now return to Q-learning. Based on the proposed ODE model, we can generate a
simulated clinical trial that provides a set of simulated finite horizon trajectories (the
training data),
{S0i, Ai0, ri0, Si1, Ai1, ri1, . . . , Ai5, ri5, Si6}1000i=1 ,
where each two-dimensional state variable St consists of (Wt,Mt), and each continuous
action variable At is a dose level Dt. In terms of optimality criterion, we seek effective
regimens that maximize a sum of numerical rewards over six months. We assume each
reward only depends on the states observed right before and after each action, that is,
when t = 0, 1, . . . , 5,
rt = R(st, at, st+1).
We decompose this reward function rt into three parts: R1(Dt,Wt+1,Mt+1) due to sur-
vival status, R2(Wt, Dt,Wt+1) due to wellness effects, and R3(Mt, Dt,Mt+1) due to tumor
size effects. It can be described by:
R1(Dt,Wt+1,Mt+1) = −60, if patient died,
otherwise,
R2(Wt, Dt,Wt+1) =

5 if Wt+1 −Wt ≤ −0.5,
−5 if Wt+1 −Wt ≥ 0.5,
0 otherwise,
R3(Mt, Dt,Mt+1) =

15 if Mt+1 = 0,
5 if Mt+1 −Mt ≤ −0.5, but Mt+1 6= 0,
−5 if Mt+1 −Mt ≥ 0.5,
0 otherwise.
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In most phase III clinical trials, the primary endpoint of clinical interest is the overall
survival (OS), that is why we put −60 as a high penalty for patient’s death. Additionally,
we assigned the relative high value 15 as a bonus when a patient is cured.
We assume that survival status depends on both toxicity and tumor size. For each
time interval (t− 1, t], t = 1, . . . , 6, we define the hazard function as λ(t), where
logλ(t) = µ0 + µ1Wt + µ2Mt,
and µ0, µ1, and µ2 are constant pre-specified parameters. In particular, assigning µ1 =
µ2 = 1 indicates that we consider wellness and tumor size to have an equally weighted
influence on the survival rate. The survival function is
∆F (t) = exp [−∆Λ(t)],
where ∆Λ(t) =
∫ t
t−1 λ(s)d(s) is the cumulative hazard function. The reason the term
R1(Dt,Wt+1,Mt+1) is expressed as a function of Wt+1 and Mt+1 is that the hazard func-
tion is only determined by the states at the end of each time interval. The conditional
probability of death for each time interval is p = 1 −∆F (t). The survival status (with
death coded as 1) is drawn according to a Bernoulli distribution B(p). Overall, by letting
γ = 1 (we would like to fully consider maximizing rewards in the long run), the one-step
Q-learning with recursive form is utilized:
Qt(St, At)← rt + max
at+1
Qt+1(St+1, At, at+1),
where rt = R1(Dt,Wt+1,Mt+1) +R2(Wt, Dt,Wt+1) +R3(Mt, Dt,Mt+1), t = 0, . . . , 5.
To obtain the estimator Q̂t, we apply SVR and ERT respectively for fitting Qt back-
ward, and save the results as {Q̂5, Q̂4, . . . , Q̂0}. Figure 7 illustrates the treatment plan
and relevant Q-function estimation procedures. Because of the inner product property
of the kernel in SVM/SVR, scaling the data before applying SVR is very important.
Another advantage for scaling is to avoid states with greater numeric ranges dominating
those with smaller numeric ranges. In our simulation studies, every variable is scaled to
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zero mean and unit variance, and the center and scale values are saved and used for later
predictions. To do fitting of Q̂t via SVR, we select the Gaussian kernel (or Radial Basis
Function), K(x,y) = exp (−ζ‖x− y‖2), because the Gaussian kernel can nonlinearly
map samples into a higher dimensional space. Consequently, it can handle the case when
the relation between rewards (labels) and states and actions (attributes) is nonlinear. In
the SVR approach there are two hyperparameters involved with the Gaussian kernel: ζ
and the tuning parameter C. To maximize the performance of the proposed method, we
apply a grid search to choose C and ζ by using cross-validation. Trying exponentially
growing sequences of C and ζ is recommended as a practical method to identify good
hyperparameters. Specifically, for each t in our simulated example, given a straightfor-
ward coarse grid search with C = 2−5, 2−3, . . . , 215 and ζ = 2−15, 2−13, . . . , 23, we apply
cross-validation to each candidate pair (C, ζ), and then select the pair that yields the
highest cross-validation rate. To fit Q̂t via ERT, we need to be careful with the choice
of parameters G, K and nmin. Based on empirical studies, Geurts et al. (2006) suggest
that the default value of K should be equal to the number of attributes in the regression
problem. Thus we fix K as the dimension of state variables plus the dimension of action
variables, which is equal to 3 in our case. To maintain good precision and small bias, G
and nmin have been chosen equal to 50 and 2, respectively.
In order to evaluate how the above estimated treatment policies perform, we generate
an additional 200 patients having initial values W0 and M0 randomly chosen from the
same uniform distribution adopted in the training data. Based on the sequential estima-
tor {Q̂5, Q̂4, . . . , Q̂0}, when t = 0, 1, . . . , 5, the individualized optimal policy calculations
are carried out using:
pit = argmax
at
Q̂t(st, at; θˆt).
The entire algorithm for Q-function estimation and optimal regimen discovery is
summarized as follows:
1. Inputs: a set of training data consisting of attributes x (states st, actions at) and
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index y (rewards rt), i.e., {(st, at, rt)i, t = 0, . . . , T, i = 1, . . . , N}.
2. Initialization: Let t = T + 1 and Q̂T+1 be a function equal to zero on St ×At.
3. Iterations: repeat computations until stopping conditions are reached (t = 0):
(a) t← t− 1.
(b) Qt is fitted with the support vector regression (SVR) or extremely randomized
trees (ERT) through the following recursive equation:
Qt(st, at) = rt + max
at+1
Qt+1(st+1, at+1).
(c) Use cross-validation to choose tuning parameters C and ζ to fit Qt via SVR
with Gaussian kernel; choose plausible values of parameters K,G, nmin, and
fit Qt via ERT (K = 3, G = 50, nmin = 2 in our simulation).
4. Given the sequential estimates of {Q̂0, Q̂1, . . . , Q̂5}, the sequential individualized
optimal polices {Â0, . . . , Â5} for new patients in the testing dataset can be predicted
one by one.
4.2.3 Simulation Results
In our analysis, we first evaluate the operating characteristics of 10 different constant
doses (0.1, 0.2, . . ., 0.9, 1.0). For comparison, we also evaluate patients’ subsequent
outcomes (Wt and Mt) conducted by our estimated optimal regimens. In addition, we
examine the properties of cumulative survival probability and the computed optimal
strategies. All of these numbers are averaged over 200 repeated simulations. When the
simulated testing trial ends at t = 6, all the results of our comparison are summarized in
Table 1.
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We used a sample size of 1000 for our simulated clinical reinforcement trial and esti-
mated the optimal treatment policy using both SVR and ERT. For the sake of simplicity,
unless stated explicitly otherwise, we only show figure results for the SVR method, since
we obtain very similar results when we estimate optimal therapy using ERT. On Figure 8
and 9, trajectories (wellness and tumor size, respectively) that would have been observed
by putting the patients on constant-dose regimens have been plotted. Note that the
wellness measure has been inverted so that larger values represent worse health. This is
to make comparisons with tumor size more direct. We test the behavior of estimated op-
timal regimens on 200 new simulated patients by comparing the outcomes using pit from
the Q̂t (t = 0, . . . , 5) against the results obtained using 10 different fixed Dt (t = 0, . . . , 5)
in the ODE model. As shown in both Figure 8 and Figure 9, the optimal regimens de-
rived from Q-learning do not have better performance compared to some constant dosing
regimens. This is not beyond our expectation. Because when higher dose level decreases
tumor size, it can bring a higher toxicity simultaneously, and vice versa. However, due
to our reward functions structure, the estimated optimal policies have an appealing fea-
ture to seek a good balance between toxicity and efficacy. Figure 10 illustrates that the
estimated optimal regimen is absolutely superior to any constant-dose regimen when we
combine toxicity and efficacy (Wt+Mt) as one comparison criterion. Table 1 agrees with
this conclusion by respectively presenting W6 + M6 = 3.269 (SVR) or W6 + M6 = 3.194
(ERT) as the lowest number compared to the others. Most notably, although the regi-
men derived from simulated data shows suboptimal results in the first three months, it
achieves the best performance eventually. These findings agree well with reinforcement
learning’s substantially powerful long-run capabilities.
Figure 11 provides the dynamic optimal regimen for an individual patient as well
as the effect values (toxicity and efficacy) in the whole trial. This simulated patient
comes into the trial with initial condition W0 = 0.30 and M0 = 1.05. Optimal therapy
begins with a very high dose D0 = 1.00 aimed at reducing the patient’s tumor burden.
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The patient is then monitored for the following month and then treated with another
two consecutive high doses (D1 = 0.74, D2 = 1.00). In the third month, the tumor size
suddenly reaches 0, i.e., the patient has been cured. As expected, we find that the dosage
to be administrated rapidly reduces to 0 in the following months. Patients who recover
after three months will not receive high dosing anymore because the high dose will likely
result in unnecessarily high toxicity. As we can see, rather than the constant dose level
for each t, optimal therapy usually has an up-and-down structure due to its adaptive
properties. This is an important result to demonstrate that the optimal policy can be
approximated very well by reinforcement learning.
At last, compared to all fixed-level doses, Table 1 and Figure 12 clearly show that
the therapy found using the Q-learning approach with either SVR and ERT has better
performance in terms of cumulative survival probability (CSP) over 6 months. Table 1
also shows that both SVR and ERT appear to perform equally well with comparable
computational burden. Additionally, we plot the average optimal strategies (regimens)
in Figure 13. As we can see, rather than the constant dose level for each t, optimal
therapy usually has an up-and-down structure due to its adaptive feature.
4.2.4 Summary of Virtual Cancer Trial Results
We have developed a reinforcement learning method for discovering effective therapeutic
regimens in clinical trial design. To investigate the validity of such a purely data (model-
free) driven approach, we have generated clinical data by relying on a set of hypothetical
(and simplistic) but plausible ODE models. Based on these simulated data, we have found
that reinforcement learning is indeed able to identify individualized optimal regimens in
clinical trials which consists of multiple courses of treatment. Such regimens can reduce
tumor burden while taking into account a drug’s toxicity. Treatment delay effects, which
is an important issue that must be considered for longer term outcomes, are fully assessed
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by this method. Another appealing feature of our approach is the incorporation of Q-
learning methodology with SVR and ERT. Hence even in a data set comprised of high-
dimensional attributes, our method is capable of obtaining promising results without
much computational burden.
Since a choice of reward function plays a crucial role in reinforcement learning, there-
fore, it is very important to consider alternative rewards directly reflecting primary end-
points (such as overall survival, progression-free survival, side effects, etc.) in clinical trial
designs. One of many feasible approaches is to perform retrospective analysis to identify
clinical factors that influence the outcome of patients treated with chemotherapy drugs,
and to build a model that can be used in practice to predict long-term survival in this
patient population. Such a model may assist us in building a more plausible reward
function, and thereafter determining a regimen which is as close as possible to an opti-
mal policy. To conduct such clinically relevant reward functions, we believe that close
collaboration with clinical researchers is required. An interesting illustrative example of a
related strategy is shown by Ernst et al. (2006). They consider discounted instantaneous
costs (which is a continuous function directly associated with actions) as their reward
function: the rationale behind this comes from a validated and identified HIV model
(Adams et al., 2004).
Since the work of this study is motivated by the clinical question of proper treatment
for Stage IIIB/IV NSCLC, as examined by several clinical trials conducted at the UNC
Lineberger Comprehensive Cancer Center (LCCC), an important application is to refine
our model to more accurately reflect NSCLC and the associated treatment issues. The
goal of the study is to compare strategies for multiple lines of treatment for patients
with advanced NSCLC who have not been treated previously with systemic therapy.
In Chapter 5 we will apply reinforcement learning to discover individualized optimal
regimens while restricting attention to first-line and second-line only, since there is only
one approved agent (Erlotinib) indicated for third-line treatment (Shepherd et al., 2005).
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Figure 6: Representation of the disease progression for a patient treated with a ran-
domized chemotherapy drug. The solid curve represents the negative part of patient’s
wellness, the dashed curve represents the tumor size, and the dotted curve represents the
randomized treatment.
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W0,M0 W1,M1 W4,M4 W5,M5 W6,M6
D0 D1 D4 D5
Q̂0 = r0 +max Q̂1
Q̂1 = r1 +max Q̂2
Q̂4 = r4 +max Q̂4
Q̂5 = r5
r0 r1 r4 r5
1
Figure 7: Treatment plan and the procedure for obtaining the sequential estimator
{Q̂5, Q̂4, . . . , Q̂0}.
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Figure 8: Plots of averaged value of “wellness” for 10 different constant-dose regimens
compared to optimal regimen. The results are based on 200 patients. Dashed curves
represent the constant-dose regimens, and a solid curve represents the optimal regimen.
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Figure 9: Plots of averaged value of “tumor size” for 10 different constant-dose regimens
compared to optimal regimen. The results are based on 200 patients. Dashed curves
represent the constant-dose regimens, and a solid curve represents the optimal regimen.
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Figure 10: Plots of averaged value of “wellness + tumor size” for 10 different constant-
dose regimens compared to optimal regimen. The results are based on 200 patients.
Dashed curves represent the constant-dose regimens, and a solid curve represents the
optimal regimen.
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Figure 11: Representation of the optimal treatment for a patient with W0 = 0.30 and
M0 = 1.05. The optimal treatment sequence (Dt ∈ {1.00, 0.74, 1.00, 0.04, 0.01, 0.01})
is computed by the reinforcement learning methods on clinical data generated by 1000
patients. The solid curve represents the negative part of patient’s wellness, the dashed
curve represents the tumor size, and the dotted curve represents the estimated optimal
regimen.
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Figure 12: Bar plots of averaged cumulative survival probability at 6 months for 10
different constant-dose regimens compared to optimal regimen. The results are based on
200 patients.
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Figure 13: The averaged optimal sequential therapies (Dt ∈ {0.72, 0.51, 0.27, 0.43, 0.32,
0.30}) for 200 patients. Dashed curves represent constant-dose regimens, and a solid
curve represents the optimal regimen.
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5 Reinforcement Learning Treatment Strategies Based
on Support Vector Regression in a Non-small Cell
Lung Cancer Trial
5.1 Introduction
In Chapter 4 we utilized reinforcement learning to discovery optimal regimen for a virtual
cancer trial. In this chapter, we will further extend our methodology to directly address
the assessment of first and second lines of treatment in advanced non-small cell lung
cancer (NSCLC).
There has been significant recent research activity in developing therapies that are tai-
lored to each individual. Finding such therapies in treatment settings involving multiple
decision times is a major challenge. For example, in treating advanced NSCLC, patients
typically experience two or more lines of treatment, and many studies demonstrate that
three lines of treatment can improve survival for patients. Discovering tailored therapies
for these patients is a very complex issue since effects of covariates (such as established
prognostic factors or biomarkers) must be modelled within the multi-stage structure. In
this dissertation, we present a new kind of NSCLC clinical trial, based on reinforcement
learning methods from computer science, that statistically finds an optimal individualized
treatment plan at each decision time which is a function of available patient prognostic
information.
For NSCLC patients who present with a good performance status and stage IIIB/IV
disease, platinum-based chemotherapy is the primary treatment which offers a modest
survival advantage over best supportive care (BSC) alone. First-line treatment primarily
consists of doublet combinations of platinum compounds (cisplatin or carboplatin) with
gemcitabine, pemetrexed, paclitaxel, or vinorelbine (Scagliotti et al., 2008; Sandler et
al., 2006; Pirker et al., 2008). These drugs modestly improved the therapeutic index
of therapy, but no combination seemed superior. More recently, the addition of beva-
cizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to
carboplatin and paclitaxel has been shown to produce a higher response rate and longer
progression-free survival and overall survival times (Sandler et al., 2006). However, this
phase III study was only designed to investigate patients with histologic evidence of
non-squamous cell lung cancer. Therefore, in first-line treatment of NSCLC trial, a
very important clinical question is what tailored treatment to administer based on each
individual’s prognostic factors (including the patient’s histology type, toxicity profile,
smoking history, and VEGF level, etc.), among many approved first-line treatments.
All patients with advanced NSCLC who initially received a platinum-based first-line
chemotherapy inevitably experience disease progression. Approximately 50-60% of pa-
tients on recent phase III first-line trials received second-line treatment (Sandler et al.,
2006). Similar to the first-line regimen, three FDA approved second-line agents (doc-
etaxel, pemetrexed, and erlotinib) appear to have similar response and overall survival
efficacy but very different toxicity profiles (Shepherd et al., 2000; Ciuleanu et al., 2008;
Shepherd et al., 2005). The choice of agent should also mainly depend on a number
of factors, including the patient’s comorbidities, toxicity from previous treatments, and
the risk for neutropenia. A better understanding of prognostic factors in the second-line
setting may allow clinicians to better select patients for second-line therapy and lead to
better designed second-line trials.
The current standard treatment paradigm is to initiate second-line therapy at the
time of disease progression. Recently there have been two phase III trials that have
investigated other possible timings of initiating second-line therapy (Fidias et al., 2007;
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Ciuleanu et al., 2008). Both of these trials have revealed a statistically significant im-
provement in the progression-free survival, and a trend towards improved survival for the
earlier use of second-line therapy. However, in terms of considering overall survival as
the primary endpoint, a nonsignificant difference has been also revealed by these two tri-
als. Stinchcombe and Socinski (2009) claimed that even under the best of circumstances
not all patients will be benefit from the early initiation of second-line therapy. Hence
the proper selection of patients is also critical to determining the proper time for initi-
ation. Hence, despite the difficulty of discovering the individualized superior therapies
in second-line treatment, another primary challenge is to determine the optimal time
to initiate second-line therapy, either to receive treatment immediately after comple-
tion of platinum-based therapy, or to delay to another time prior to disease progression,
whichever results in the largest overall survival probability. The goal is to provide pa-
tients with non-cross-resistant therapies capable of obtaining better response rates and
longer survival time.
Some patients who maintain a good performance status and tolerate therapy without
significant toxicities will receive third-line therapy (Stinchcombe and Socinski, 2008).
Since there is only one FDA approved agent (Erlotinib) available for third-line treatment,
we restrict our attention to finding optimal therapies for first-line and second-line only.
Figure 14 illustrates the treatment plan and clinically relevant patient outcomes.
Therapy begins with first-line platinum-based doublets aimed at improving survival and
palliating disease-related symptoms without undue toxicity. The patient is then deliv-
ered to no more than 8 cycles of treatment as recommended by the American Society
of Clinical Oncology (ASCO). Socinski and Stinchcombe (2007) suggest the standard
initial duration of platinum-based therapy should be 3 to 4 cycles since four of the five
trials investigating the duration of platinum therapy in the first-line setting have revealed
equivalent survival with the shorter duration of therapy. Due to the effects of the ini-
tial treatment, generally patients experience disease progression within a median of 3-6
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months, and the median survival time observed is 8 to 10 months (Schiller et al., 2002;
Sandler et al., 2006). Approximately 30–40% of patients survive 1 year, and less than
15% survive 2 years (Bunn and Kelly, 1998). If the first line of treatment is successfully
completed without progression or death, then a second line of therapy is administered
sometime between the completion of first-line treatment and the time of first evidence of
disease pregression. Patients with a good performance status in second-line trials have a
median survival duration of approximately 9 months (Stinchcombe and Socinski, 2008).
Given the noncurative nature of chemotherapy in advanced NSCLC, the overall survival
time is defined as the primary endpoint.
The primary scientific goal of the trial is to select optimal compounds for first and
second-line treatments as well as the optimal time to initiate second-line therapy based
on prognostic factors yielding the longest averaged survival time. We create such new
trial based on a reinforcement learning method, called Q-learning, for maximizing the
averaged survival time of subgroup patients as a function of prognostic factors, treatment
decisions, and optimal timing. We take the reinforcement learning approach because de-
cisions must be made adaptively to various individuals during the trial, and this problem
is especially acute in multi-stage treatment. In Chapter 4 we introduced Q-learning to
cancer clinical communities and created a clinical reinforcement trial for discovering ef-
fective therapeutic regimens. By taking into account a drug’s efficacy and toxicity simul-
taneously, we demonstrated that reinforcement learning methodology not only captures
the optimal individualized therapies successfully, but also is able to improving longer-
term outcomes by considering delayed effects of treatment. While the trial proposed in
Chapter 4 used to identify the optimal treatment shares similarity to some cancers, the
structure (referred to optimal timing) is very different from NSCLC, so significant re-
finement for different optimal strategies identification is needed. Another challenge may
also arise due to the right censoring phenomena in realistic trials, and we will address
this issue in our new clinical reinforcement trial for NSCLC. In addition, in Chapter 4
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we just utilized simplistic integer numbers as the reward function in Q-learning to trade
off efficacy against toxicity. Thus it is important to consider some more plausible utility
functions such as progression-free survival, overall survival, or quality of life to reflect the
primary endpoint directly. In general cases, based on different reward functions chosen
by clinicians, optimal treatment strategies found by a clinical reinforcement trial could
be possibly more than one. In our NSCLC trial, we focus our attention on overall sur-
vival and treat it as the reward function, since this is arguably the most crucial clinical
outcome, although quality of life is also important.
The design has two main components: a clinical reinforcement trial for fair randomiza-
tion of patients among the different therapies in first and second-line treatments, as well
as time of initiating second-line therapy, and a confirmatory phase III trial for finding and
validating the optimal individualized therapies. Each new patient in the confirmatory
trial is more likely to be assigned at appropriate treatments and timing having longest
overall survival time, based on the performance of estimated optimal policies which are
learned from the clinical reinforcement trial. In order to successfully handle the complex
fact of heterogeneity in treatment across individuals and the possibility of right censored
individuals in an NSCLC trial, we incorporate a modified SVR called -SVR-C within a
Q-learning framework to fit Q-functions for each decision point.
The remainder of this chapter is organized as follows. In Section 5.2 – 5.3, we provide
a detailed description of the patient outcomes and refined Q-learning framework, followed
by an introduction to -SVR-C for estimating Q-functions with censored observations.
The NSCLC trial conduct and related computational issues are presented in Section 5.4.
In Section 5.5, we present a simulation study of the design to discover individualized
optimal treatment strategies. We close with a summary in Section 5.6.
70
5.2 Reinforcement Learning Model Refinement
5.2.1 Patient Outcomes
Let t1 and t2 denote the decision time of first and second line treatment, respectively.
Given first-line chemotherapy, the indicator of the time to disease progression is denoted
by TP . t2 is also the time at the completion of first-line treatment, and is a fixed value
usually less than TP and determined by the number of cycles delivered in the first line of
chemotherapy. Denote the time of initiating second-line therapy by TM . Thus, according
to the description of treatment plan in Section 5.1, TM ∈ [t2, TP ]. At the end of first-line
therapy, t2, clinicians make a decision when to start TM . We let TD denote the time of
death from the start of therapy, i.e., the overall survival time. For patients who have
died before t2, let T1 denote the time from t1 to patient’s death. In this case, TD = T1.
Similarly, for patients who live beyond t2, let T2 denote the time from t2 to patient’s
death. Thus, for this kind of patient, TD = t2 + T2. Note that TD may less than TM .
Because of the possibility of right censoring, we define the patient’s censored time by
C and the indicator of censoring by δ. Right censoring may be due to several reasons,
including an adverse event so severe that therapy cannot be continued or the patient
chooses not to receive further therapy. We assume for simplicity that censoring is in-
dependent of death in this thesis. For convenience, we let YD = I(TD ∧ C > t2) and
ν = Pr(YD = 1), so T2 is defined only if YD = 1 and δ = 0. Denoting the last follow-up
time by T 0, we then can define T 0 = TD ∧ C ∧ t2 + I(TD ∧ C > t2)(T2 ∧ (C − t2)). The
settings for determining T1, C, TM , and T2 are summarized in Figure 15, including the
possibilities of death or right censoring either before or after second-line therapy.
Denote patient covariate values at the ith line by Oi = (Oi1, . . . , Oiq) for i = 1, 2.
Such covariates can include prognostic variables or biomarkers thought to be related
to outcome. In first-line therapy, we assume that the death time T1 depends on the
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covariates O1 and possible treatment D1 according to a possible function
[T1 | O1, D1] ∼ f1(O1, D1;α1),
where decision D1 only consists of a finite set of agents d1. If the patient survives long
enough to be treated by second-line therapy, we assume that the disease progression time
TP follows another distribution
[TP | O1, D1] ∼ f2(O1, D1;α2).
In addition, to account for the effects of initial timing of second-line therapy on survival,
T2 is given by
[T2 | O2, D1, D2, TM ] ∼ f3(O2, D1, D2, TM ;α3),
where D2 consists of a finite set of agents d2 and TM is a continuum of initiation times
for second-line therapy as described above. Therefore, this study is designed to identify
the the initiation time, TM , that is associated with the best combination of treatments
d1 and d2, while maintaining longest survival TD. Due to heterogeneities among patients,
biomarker-treatment interactions, and the large number of possible shapes of T2 as func-
tions of TM , functions f1, f2, and f3 can be linear or non-linear and may vary between
different groups of patient. Thus, incorporating Oi into model fi (i = 1, 2, 3) is quite
challenging, and such model-based approaches can easily become intractable (Thall et
al., 2007). Another important issue is accounting for delayed effects of first-line therapy.
It is possible that the treatment having a short disease progression time TP , by admin-
istering first-line therapy, is a good strategy for two-stage treatment protocols in terms
of overall survival time. Thall et al. (2007) claimed that the conventional model-based
approaches are not capable of handling this situation very well. Based on clinical data,
reinforcement learning is not only a model-free method which carries out treatment se-
lection sequentially with time-dependent outcomes to determine optimal individualized
therapy, but it can also improve longer-term outcomes by taking into account delayed
effects of treatments.
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5.2.2 Q-Learning Revisited
As mentioned in Section 3.2.2, the Q-learning (Watkins, 1989; Watkins and Dayan, 1992)
is one of the most widely used reinforcement learning methods. The core of the algorithm
is a simple value iteration update. It assumes the old value and makes a correction based
on the new information as follows (Sutton and Barto, 1998):
Qt(st, at)← Qt(st, at) + αt(st, at)×
[
rt + γmax
at+1
Qt+1(st+1, at+1)−Qt(st, at)
]
, (5.1)
where rt is the current reward given at time t, αt(st, at) ∈ (0, 1] the learning rate (or
learning step-size). We let γ = 1 to fully maximize rewards over the long run. For
simplicity of computation, we ignore the step-size (let αt(st, at) = 1) for the rest of the
article. All results hold with minor modifications when the step-size effects are considered.
Then model (5.1) can be simplified to one-step simple recursive form
Qt(st, at)← rt + max
at+1
Qt+1(st+1, at+1). (5.2)
The Q-learning algorithm attempts to find a policy pi that maps states to actions the
learner ought to take in those states. pi is possibly deterministic, non-stationary, and
non-Markovian. We denote the optimal policy by pi∗t , which satisfies
pi∗t = argmax
at
Qt(st, at).
In Chapter 4 we performed a simulation study of a simple Q-learning approach with
6 decision time points for discovering optimal dosing for treatment of a generic cancer.
While the results were encouraging, there remains much work to do before these meth-
ods can be applied to realistic cancer scenarios. For example, in Chapter 4, the choice
of treatments at each decision time point is taken from a continuum of dosing levels.
However, in NSCLC treatment with two decision time points, the action variables in the
second stage become two-dimensional (d2 and TM). Due to this significantly different
structure, a new methodology and model are needed. Moreover, the presence of cen-
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soring in the reward outcome means that a fundamentally new approach is required for
estimating the Q functions.
In our clinical setting we respectively denote state and action random variables by Oi
and Di for i = 1, 2. This is consistent with notations of prognostic factors or biomarkers
and treatment options used in Section 5.2.1. As mentioned in Section 5.1, we consider
survival time as the primary reward function. Specifically, by performing a treatment
d1, where d1 ∈ D1, the patient can transit from first line to second line. Such treatment
associated with prognostic factors provides the patient a progression time TP and T1 (T1
is defined only if YD = 0). TP is only used for determining TM . Moreover, D2, which
consists of two dimensional action variables including a possible discrete action (agent) d2
mixed with a continuous action (time) TM , provides the patient a survival time T2. While
taking into account possible right censoring in the first stage, such a reward function can
be formally defined as T1 ∧ C, plus the corresponding censoring indicator, if YD = 0 or
t2 if YD = 1, where T1 satisfies
T1 ∼ R1(o1, d1).
In the second stage, the reward function is defined by T2 ∧ (C − t2), where T2 satisfies
T2 ∼ R2(o2, d1, d2, TM).
Functions R1 and R2 coincide with f1 and f3 and are not observable in realistic trials. In
Q-learning, because for every state there are a number of possible treatments that could
be taken, each treatment within each state has a value according to how long the patient
will survive due to completion of that treatment. The scientific goal of our study is to find
an optimal policy to maximize patients’ overall survival time TD. This is accomplished
by learning which treatment (including starting time for second-line therapy) is optimal
for each state.
While learning a non-stationary non-Markovian optimal policy with one set of finite
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horizon trajectories (also called a training data set)
{O1, D1, TD ∧ C ∧ t2, O2, D2, T2 ∧ (C − t2), δ},
we denote the estimation of the optimal Q-functions based on this training data by Q̂t,
where t = 1, 2, 3. According to the recursive form of Q-learning in (5.2), we must estimate
Qt backwards through time, that is, use the estimate Q3 from the last time point back
to Q1 at the beginning of the trial. For convenience we set Q3 equal to 0. In order to
estimate each Qt, we denote Qt(Ot, Dt;θt) as a function of a set of parameters θt, and
we allow the estimator to have different parameter sets for different time points t. Once
this backwards estimation process is done, we save the sequence of Q̂1 and Q̂2, and we
thereafter use them to respectively estimate optimal treatment policies
pi1 = argmax
d1
Q̂1(o1, d1;θ1)
and
pi2 = arg max
d2,TM
Q̂2(o2, d2, TM ;θ2),
for new patients in a testing dataset. These estimated optimal policies should also be
evaluated in a follow-up confirmatory phase III trial comparing the optimal policy or
policies with the standard of care.
5.3 Support Vector Regression for Censored Subjects
A strength with Q-learning is that it is able to compare the expected survival of the
available treatments without requiring a model of the relationship. To achieve this, the
main task is to estimate the Q functions for finding the corresponding optimal policy.
However, challenges may arise due to the complexity of the structure of the true Q
function, specifically, the non-smooth maximization operator in recursive equations (5.2).
In the previous chapter we applied SVR as our main method to fit Q functions and
learn optimal policies using a training data set. Instead of the hinge loss function used
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in SVM, one of the popular loss functions involved in SVR is known as the -insensitive
loss function (Vapnik, 1995), which is defined as
L(f(xi), yi) = (|f(xi)− yi| − )+, (5.3)
where  > 0.
Note that we have in the prior chapter assumed that all patients are followed up until
they die. In conducting an NSCLC trial, a common problem is the right censoring caused
by patients who do not complete the study and drop out of the study without further
measurements. Possible reasons for patients dropping out of the study include, adverse
reactions, lack of improvement, unpleasant study procedures, and other factors related
or unrelated to the trial procedure and treatments. For simplicity, we assume that right
censoring is independent of death.
In general, we denote interval censored data by (xi, li, ui)
n
i=1. If the patient experiences
the death event and TD is observed rather than being interval censored then we include
TD and denote such observation as (xi, yi). In other words, when we observe TD exactly
(δ = 0), we let li = ui = yi. Note that by letting ui = +∞ we can easily obtain a right
censored observation (xi, li,+∞).
One naive way to handle censored data within Q-learning by using SVR is to consider
only those samples for which the survival time TD are known exactly. Such an approach
which totally ignores censored data will reduce the sample size for statistical analysis and
inference. Thus the more patients that are censored, or the earlier they are censored,
the more unreliable the results will be. An SVR procedure that targets interval censored
subjects was introduced by Shivaswamy, Chu, and Jansche (2007). The key component
of their procedure is a loss function, defined as
L(f(xi), li, ui) = max(li − f(xi), f(xi)− ui)+.
However, this loss function dose not have -insensitive properties, that is, it does not
allow  or other deviations from the predicted f(xi), especially when li = ui = yi. In
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this article, we propose a modified SVR algorithm with -insensitive loss function (called
-SVR-C) to make use of both survival time TD and censoring time C in the data set
and to reduce the potential bias which may caused by performing a classical SVR with
censored data.
Given the interval censored data set (xi, li, ui)
n
i=1, our modified loss function is defined
as
L(f(xi), li, ui) = max(li − − f(xi), f(xi)− ui − )+. (5.4)
The main difference between (5.3) and (5.4) is that yi is separated into two parts which
are replaced by li and ui, respectively. We remark that this loss function does not penalize
values of f(xi) if it is between li− and ui+. On the other hand, the cost grows linearly
if this output is more than ui +  or less than li − . Figure 16 shows the loss function
of the modified SVR. Note that when ui = +∞, this loss function becomes one sided,
which means there is no empirical error if f(xi) ≥ li − . In addition, when the data is
not observed as censored, our modified SVR algorithm reduces to the classical SVR.
The parameter  can be useful if the desired accuracy of the approximation can
be specified beforehand. Note that when  = 0, our approach reduces to the method
proposed by Shivaswamy et al. (2007). Based on some small simulation studies, the
performance of our method is not very sensitive to the choice of  (say, from 0 to 0.1).
This means, in our study, -SVR-C’s performance is very close to Shivaswamy et al.
(2007)’s method. However, since -insensitive tube is useful to control the proportion of
support vectors involved in approximation, we prefer -SVR-C throughout this thesis.
Denoting index sets L = {i : li > −∞} and U = {i : ui < +∞}, the corresponding
modified SVR optimization formulation is:
min
w,b,ξ,ξ′
1
2
‖w‖2 + C
(∑
i∈L
ξi +
∑
i∈U
ξ′i
)
,
subject to (wTΦ(xi) + b)− ui ≤ + ξi, i ∈ U,
li − (wTΦ(xi) + b) ≤ + ξ′i, i ∈ L,
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ξi ≥ 0, i ∈ L; ξ′i ≥ 0, i ∈ U.
Similarly to classical SVR, the dual can be presented as follows by introducing Lagrange
multiplier λi:
min
λ,λ′
1
2
(λ− λ′)TK(xi,xj)(λ− λ′)−
∑
i∈L
(li − )λ′i +
∑
i∈U
(ui + )λi,
subject to
∑
i∈L
λ′i −
∑
i∈U
λi = 0,
0 ≤ λi, λ′i ≤ C, i = 1, . . . , n.
Once the above formulation is solved to get the optimal λi and λ
′
i, the approximate
function at x is given by:
f(x) =
n∑
i=1
(λ′i − λi)K(xi,x) + b.
Based on results for non-censored Q-learning with classical SVR, it is expected that the
-SVR-C behaves similarly, with the estimated policies pi being more robust to censored
data and being more optimal than results where the censored patients are simply ignored.
To verify this comparison, a small simulation study will be reported in Section 5.5.
5.4 Clinical Reinforcement Trial Conduct and Computational
Strategy
Different populations of patients with NSCLC appear to have different clinical and molec-
ular characteristics, so clinical trials that investigate the activity of different agents, and
incorporate patient selection based on clinical factors, are required. The goal of this
clinical reinforcement trial is to compare two-line treatment strategies for patients with
NSCLC who have not been treated previously with systemic therapy. As mentioned in
Section 5.1, while many new single agents with potential clinical efficacy currently are
being produced at an increasing rate, the number of doublet combinations in the first
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line that can be evaluated clinically is limited. Considering the number of possible agents
that may be of interest in the second line, the limitations are far greater.
Without loss of generality, suppose for simplicity that strategies are based on four
FDA approved therapies (either single agents or doublets), which we denote by Ai, i =
1, . . . , 4. In our study we assume that the second line treatment must be different from
the first. When designing the trial, two of the four agents A1 and A2 are selected for
first-line treatment, while A3 and A4 are selected for second line. A total of n patients
are recruited into the trial and fairly randomized at enrollment between A1 and A2, and
each patient is followed through to completion of first-line treatment, given the patient is
not dead or lost to follow-up from the study. We fix this duration t2 − t1 as 2.8 months,
although other lengths are possible, depending on the number of cycles of treatment.
At the end of first-line treatment, patients are randomized again between agents A3 and
A4. Moreover, another important clinical decision that needs to make at this point is
when to initiate the second-line treatment. Thus, the initiation for second-line treatment
could be randomized to as early as t2 or as late as TP (recall that TP denotes the time of
patient’s disease progression). At the end of the trial, the patient data is collected and
Q-learning is applied, in combination with SVR applied at each time point, to estimate
the optimal treatment rule as a function of patient variables and biomarkers, at t1 and
t2.
The trial described above was motivated by the desire to compare several agents as
well as timing in a randomized fashion, the belief that different agents combined with
different timing given consecutively may have interactive effects for separate population
of patients, and the desire to determine a sound basis for selecting individualized optimal
strategies for evaluation in a future clinical trial. Computationally, the entire algorithm
for Q-function estimation and optimal treatment discovery is summarized as follows:
1. Inputs: If t = 1, a set of training data consists of attributes xi (states o1, actions
d1) and index yi (rewards T1 ∧ C), i.e., {(o1, d1, T1 ∧ C, δ)i, i = 1, . . . , n}; if t = 2,
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a set of training data {(o2, d2, TM , T2 ∧ (C − t2), δ)j, j = 1, . . . , n′}, where n′ ≤ n
since patients may die or be censored before second-line therapy.
2. Initialization: Let Q̂3 be a function equal to zero.
3. Q2 is fitted with -SVR-C through the following equation:
Q2(o2, d2, TM) = T2 ∧ (C − t2).
4. Q1 is fitted with -SVR-C through the following equation:
Q1(o1, d1) = T1 ∧ C ∧ t2 + YD × max
d2,TM
Q2(o2, d2, TM).
5. For the SVR computations in steps 3 and 4, if a Gaussian kernel is applied,
we use a straightforward coarse grid search with C = 2−5, 2−3, . . . , 215 and ζ =
2−15, 2−13, . . . , 23, evaluated at each candidate pair (C, ζ), and then select the one
that yields the highest cross-validation rate.
6. Given Q̂1 and Q̂2, the individualized optimal polices pi1 and pi2 for application to
future patients are computed.
7. Evaluate pi1 and pi2 in a confirmatory phase III trial to compare the optimal policies
with the standard of care.
5.5 Simulation Study
To demonstrate that the tailoring therapy for NSCLC found by using the proposed
clinical reinforcement trial is superior, we employ an extensive simulation study to assess
the proposed approach on virtual clinical trials of patients, and then evaluate using Phase
III trial-like comparisons between the estimated optimal regimen and the various possible
fixed treatments.
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5.5.1 Data Generating Models
Based on historical research, it is well known that the rate of disease progression or
death for patients with advanced NSCLC increases over time. Consequently, in order
to generate simulation data, we simply consider that TP , T1, and T2 follow different
exponential distributions. Many alternative models are also possible.
Let exp(x) denote an exponential distribution with mean ex. For a patient given
first-line treatment d1, we assume death time distribution
[T1 | D1] ∼ exp(αD1 + βD1W1 + κD1M1 + τD1W1M1). (5.5)
If T1 > t2, we assume disease progression time distribution
[TP | D1] ∼ exp(αPD1 + βPD1W1 + κPD1M1 + τPD1W1M1). (5.6)
Given t2, TM is uniformly generated from [t2, t2 + 4] (4 months interval). If TP ≤ TM ,
then let TM = TP . In addition, for a patient given second-line treatment d2 and initiation
time TM , we assume the death time
[T2 | D1, D2] ∼ exp(αD12 + βD12W2 + κD12M2 + h(TM ;ϕ)). (5.7)
Given TD = T1 or t2 + T2 and patient censored probability p
c, we generate right cen-
sored time C uniformly from interval [t1, t1 + 24] (2 years interval), where the censoring
indicator is drawn according to a Bernoulli distribution B(pc). Note that in our simu-
lation study we straightforwardly use exponential pdfs (5.5)–(5.7) to replace (f1, f2, f3),
which are mentioned in the notation of Section 5.2.1. For the sake of simplicity, in these
density functions only two state variables such as quality of life (QOL) and tumor size
are considered as patient prognostic factors or biomarkers to be related to outcome, and
they are denoted by Wt and Mt (t = 1, 2), respectively. We consider these two factors
because they are patient based, easy to be measured, can predict therapeutic benefit after
treatment of chemotherapy, and more importantly, they are significant prognostic factors
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for survival (Socinski et al., 2007). In addition, state variables for the next decision are
generated by simple dynamic models W2 = W1 + TMW˙1 and M2 = M1 + TMM˙1.
Recall that ν is the probability for the event that the patient can live beyond t2. The
parameter vector for patients who only experience first-line treatment is
θ1 = (αD1 , βD1 , κD1 , τD1),
otherwise, it is
θ2 = (α
P
D1
, βPD1 , κ
P
D1
, τPD1 , ν, αD12 , βD12 , κD12 ,ϕ).
Parameter vectors θ1 and θ2 as well as the shape of time-related function h(TM ;ϕ) vary
among different patients. Note that two patients who receive different decisions with the
same first-line treatment, say (A1, A3) and (A1, A4), both contribute data for learning in
stage 1.
5.5.2 Clinical Scenarios
To construct a set of scenarios reflecting the interaction between two lines of treatment,
we temporarily assume that a large portion of patients survive long enough to be treated
by second-line therapy, that is, we specified ν = 0.8 for all patients. Except for ν, each
clinical scenario under which we will evaluate the design in the simulation study is built
by a unique set of fixed values of (αPD1 , β
P
D1
, κPD1 , τ
P
D1
, αD12 , βD12 , κD12). The remaining
fixed parameter values needed for the simulations are those that determine how T2 varies
as a function of TM . To implement this, we specified four corresponding model-based
cases of each function h(TM ;ϕ) in terms of their numerical values at each TM . All of these
underscore the importance of specifying the optimal regimen to target a subpopulation
of patients with distinct characteristics.
Hence, to facilitate interpretation of reinforcement learning strategies for capturing
individualized therapies, four scenarios are specified and summarized in Table 2. In group
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1 and 4, initial timing of second-line therapy for survival time (T2) are functions that
form an inverse-U (quadratic) shape with TM , while initial timing in group 2 and 3 for T2
are functions that linearly decrease and increase with TM , respectively. Each group thus
consists of a combination (Ai, Aj) as well as TM timing from Table 2 (where i = 1, 2 and
j = 3, 4), with the fixed values of αPD1 , β
P
D1
, κPD1 , τ
P
D1
, αD12 , βD12 , κD12 , and ϕ as described
above.
Note that whatever combination of two-line treatment (Ai, Aj) is evaluated, all pa-
tients within one group share the same trend of T2 versus TM . However, we assume there
is only one strategy that will yield the longest survival time in each group. For conve-
nience, we denote “1, 2, 3” as the location of optimal initiation of second-line therapy,
defined as “immediate, intermediate, delayed”, respectively. For example, as claimed
in the last column in Table 2, A1A32 indicates that the two-line treatments (A1, A3)
along with an intermediate initiation time point is the optimal regimen for group 1.
The inverse-U-shaped function T2 for TM corresponds to the case where patients have
relatively low QOL at enrollment but relatively large tumor size, hence, this optimal
intermediate initiation of second-line therapy is recommended to delay treatment in a
short time for patients who may have severe symptoms and low tolerance of chemother-
apy, but not to be fully delayed due to the possibility of death. In scenario 2, due to the
good QOL and large tumor size at enrollment, it is optimal for the second-line therapy to
begin immediately after first-line therapy, hence, A1A41 is the optimal regimen for these
patients. Similarly, in scenario 3, treatment A2A33 is considered the superior treatment
since we believe fully that delaying the initiation of second-line therapy at the time of
disease progression will improve survival and palliate symptoms. Although scenario 4
has optimal regimen A2A42, due to the flat shape of T2 versus TM , there is no significant
improvement between delaying and not delaying the initiation of second-line therapy.
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5.5.3 Simulation Methods and Results
First, according to various (W1,M1) as described in Table 2, a clinical reinforcement trial
of size N = 100 is generated for each group (total n = 400), and we repeat this simulation
for 10 times. Q̂1 and Q̂2 are computed via the algorithm given in Section 5.3. Then
predicted optimal strategies are computed via an independent phase III confirmatory
trial of size 100 per group, generated from the same mechanism as its corresponding
reinforcement trial. For comparison, we assign all test patients to (Ai, Aj)×{immediate,
intermediate, delayed}, which consists of 12 combinations in total. Patients’ outcomes
(overall survival) conducted by our estimated optimal regimens and 12 different fixed
regimens are all evaluated. All of these results are averaged over 400 patients in each
regimen in the confirmatory trial. As shown in Figure 17, among regular regimens, by
assigning all testing patients to A2A33 will yield the averaged longest survival as 14.71
months. It thus appears that, in terms of adaptively selecting best strategies for each
group, the optimal regimen obtained by Q-learning with -SVR-C is superior due to
the averaged survival of 16.45 months (with standard deviation 0.063) over 10 trials.
Because of this encouraging result, it is worthwhile to deeply investigate whether our
approximations are close to the exact solution. To carefully examine this comparison,
we assign patients of each group to the corresponding true optimal regimen described
in Table 2. Since the reinforcement trial was simulated 10 times with a size of 400, the
minimum, maximum, and mean values of averaged predicted survival for each group are
computed based on these 10 trials, respectively. The results are summarized in Table 3.
The averaged predicted survival over all groups is shown as 16.446, this number along
with minimum 16.065 and maximum 16.624 are all pretty close to true optimal survival
16.554. In terms of estimation, under each of the scenarios 1–3 our methods perform very
similarly and slightly underestimates the true optimal survival. In contrast, our method
slightly overestimates the true optimal survival in scenario 4.
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Second, although our Q-learning method with N = 100 per group using -SVR-C
leads to an apparently small bias for estimating individualized optimal regimens, an
examination of performance influenced by the sample size is worthwhile. We repeated
the simulations 10 times for each specified sample size while varying N from 2 to 600 per
group. The results are illustrated in Figure 18, which shows that the method’s reliability
is very sensitive to N when N ≤ 80, with the averaged survival for the estimated optimal
strategy increasing from 14.017 when N = 2 to 16.320 when N = 80. The boxplots
also show that both the deviation and estimation bias of predicted survival are getting
smaller when the sample size becomes larger. When N ≥ 100, our methods appear to
do a very reliable job of selecting the best strategy. Hence, in the setting we study here,
the sample sizes required to reach excellent approximation are similar to and not larger
than the sizes required for typical phase III trials.
Third, in order to compare performance of the -SVR-C for censored subjects to non-
censored and ignoring the censored cases, from 400 training samples over 10 simulations
run, we randomly select a fraction of the samples (based on censored data simulation
described in Section 5.5.1) so that they become right censored patients. We repeat the
comparisons with reinforcement trial which has 25%, 50%, and 75% censored proportion,
respectively. The boxplots are presented in Figure 19. Evidently, in terms of averaged
predicted survival in all cases, the -SVR-C algorithm outperforms the method which
totally ignores cencored data, particularly when the censored proportion is large.
5.6 Summary of NSCLC trial results
We have proposed an adaptive reinforcement learning design for conducting a clinical
trial of multiple lines of treatment in a group of patients with advanced NSCLC. The
incorporation of Q-learning with the proposed -SVR-C appears to successfully identify
optimal treatment strategies tailored to a proper subpopulation of patients. While our
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method has been utilized for the two decision points at hand, the general principals and
algorithms of this approach could be applied, with suitable modification, to design future
trials having similar goals but for possibly different diseases.
We provided an explicit simulation to evaluate the performance of -SVR-C in rein-
forcement trials. Our analysis and simulation conclude that the Q-learning procedure
with -SVR-C can handle censored data and simultaneously maintain good estimation,
and is a practical choice for reinforcement learning designs with higher levels of censoring.
When there are no censored subjects, the -SVR-C reduces to classical SVR. When there
are large portion of censored subjects, the -SVR-C is much more robust and effective
than the naive method which just simply ignores the censored data. More simulations
and theoretical studies of -SVR-C are needed in the future.
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Figure 14: Treatment plan and therapy options for an advanced NSCLC trial.
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Figure 15: The four cases that determine the times T1, C, TM , and T2. In each case, the
time of last follow-up is indicated by a right triangle. Note that all times originate at t1
except T2 which originates at t2.
88
li −  ui +  f(xi)
L(f(xi), li, ui)
(a)
li −  f(xi)
L(f(xi), li,+∞)
(b)
1
Figure 16: Loss functions of -SVR-C for interval censored data (a) and right censored
data (b).
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Table 2: The scenarios studied in the simulation. Sample size = 100/group.
Group State Variables Status Timing Optimal Regimen
1
W1 ∼ N(0.25, σ2)
W1 ↓M1 ↑ A1A32M1 ∼ N(0.75, σ2)
2
W1 ∼ N(0.75, σ2)
W1 ↑M1 ↑ A1A41M1 ∼ N(0.75, σ2)
3
W1 ∼ N(0.25, σ2)
W1 ↓M1 ↓ A2A33M1 ∼ N(0.25, σ2)
4
W1 ∼ N(0.75, σ2)
W1 ↑M1 ↓ A2A42M1 ∼ N(0.25, σ2)
90
11.36 13.18 13.32 11.96 13.50 13.70 12.61 14.61 14.71 11.16 13.01 13.31  16.45
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0
5
10
15
20
25
A1A31 A1A32 A1A33 A1A41 A1A42 A1A43 A2A31 A2A32 A2A33 A2A41 A2A42 A2A43  optimal
Figure 17: Performance of optimal individualized regimens versus other 12 combinations.
The same confirmatory phase III trial was used in this comparison. The 12 bars in the
left indicate results of 12 different fixed regimens, while the bar in the right indicate
results of optimal regimens. The optimal regimens will yield averaged survival time of
16.45 months with standard deviation 0.063 (over 10 trials), which is longer than all fix
regimens.
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Table 3: Comparisons between true optimal regimens and estimated optimal regimens for
overall survival (month). Each training dataset is of size 100/group with 10 simulation
runs. Testing dataset is of size 100/group.
Optimal True Predicted survival
Group regimen survival Min Mean Max
1 A1A32 14.773 14.072 14.593 14.769
2 A1A41 15.343 14.941 15.197 15.341
3 A2A33 17.614 17.060 17.417 17.576
4 A2A42 18.487 18.188 18.578 18.810
Average 16.554 16.065 16.446 16.624
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Figure 18: Sensitivity of the predicted survival to the sample size.
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Figure 19: Boxplots of the predicted survival computed via Q-learning with -SVR-C
based on a reinforcement trial with 25% (a), 50% (b), and 75% (c) fraction of right cen-
sored subjects. In each case ((a),(b), or (c)), based on the same trial, 3 boxplots indicate
performance of non-censored, right-censored, and for ignoring censoring, respectively.
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6 Concluding Remarks
6.1 Overview
In this dissertation, we have developed a groundbreaking new approach to cancer clinical
trials which uses reinforcement learning (Q-learning) techniques from computer science
to discover optimal tailoring treatment regimens for cancer. The idea of using reinforce-
ment learning in clinical trials is a paradigm shift from the standard approach — of
selecting the best treatment from a small set of pre-defined treatment options assigned
to an assumed-to-be-homogeneous group of patients — to evaluating a continuum of
treatment options and optimizing over a varied range of patients with different clinical
histories and symptoms. Our work was motivated by real NSCLC trial examples from
University of North Carolina Lineberger Comprehensive Cancer Center protocol 9719,
“Phase III randomized trial comparing a defined duration versus continuous administra-
tion of combination chemotherapy in advanced non-small cell carcinoma of the lung”,
and protocol 2003, “Phase II randomized trial comparing weekly adminstration of taxol
with IIIB/IV non-small cell lung cancer”.
In Chapter 4, we performed a simulation study of a simple reinforcement learning
approach for discovering optimal dosing for treatment of a generic cancer. The disease
model is based on a simple differential equation that balances a simulated chemotherapy
agent’s efficacy and toxicity. By utilizing Q-learning, the clinical reinforcement trial
was able to find the best treatment rule for dosing of the agent based on biomarkers
available from the patient. Our approach uses SVR and ERT to fit Q functions at each
decision point. Clearly, the optimal treatment is superior by 6 months after initiation
of treatment, although it is not optimal at 2 months. This demonstrate the ability of
reinforcement learning to not only adapt to individual patient needs but to discover the
proper tradeoff between short and long term effects of treatment.
In Chapter 5, we significantly refined our reinforcement learning model for an ad-
vanced NSCLC trial to account for changes of the best two lines of treatment along with
optimal times of initiating second-line therapy across patients. Our -SVR-C method
incorporated with Q-learning models overall survival in the timing, covariate effects,
and appropriate patient heterogeneity, while taking into account right censored patients
in the loss function of SVR using all information. Our approach is powerful since co-
variate effects of patient are embedded in the design within the multi-stage structure.
Our simulations show that the method does a good job of assigning patients in favor
of a superior treatment, and that it does this reliably within subgroups when there is
treatment-covariate interaction. Simulation studies also demonstrate that our method re-
quires relatively small sample sizes to approximate true optimal therapies, and sensitivity
studies indicate that the correct selection probabilities increase with sample size.
6.2 Future Research
There are a number of challenges we expect to face in future research. First of all,
in Chapter 4 we have defined the reward as a straightforward function to map states
and actions into some integer numbers (15, 5, 0, −5 and −60). This simplistic reward
function construction along with the Q-learning represents an attractive way for trading
off efficacy against toxicity and death. However, it is unclear how changing these numbers
affects the resulting optimal regimens identified during discovery of effective therapeutic
strategies. Understanding the robustness of Q-learning to numerical reward choices is an
interesting problem and clearly deserves further investigation.
Secondly, in Chapter 4 we observed that with sample size N = 1000 for a clinical
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reinforcement trial, using SVR or ERT leads to an apparently small bias for estimat-
ing optimal regimens. The evidence for this is the confirmed success of the discovered
treatment regimen on an independent sample of 200 simulated patients. Similarly, in
Chapter 5 we studied the prediction accuracy of our method with varying sample sizes in
an NSCLC trial. The posterior analysis shows that with sample size N ≥ 100 per group
our method can yield a small estimation bias. Althoug both results indicate that good
estimation can be achieved when sample size is relatively small, this assumption may be
violated in many settings due to the complexity associated with the performance of the
approximation on the Q function, the high-dimensional state or action space, the horizon
time T , the connection with SVR or ERT, and more importantly, estimation accuracy.
Therefore, an interesting but potentially difficult question would be: how to determine an
appropriate sample size for a clinical reinforcement trial, which allows utilizing the SVR
or ERT to fit Q and can be guaranteed to reliably obtain a treatment policy that is very
close to the true optimal one? This sample size calculation is related to the statistical
learning error problem. Recently, there has been considerable interest in studying the
generalization error for Q-learning. Murphy (2005) derived finite sample upper bounds
in a closely related setting which depend on the number of observations in the training
set, the number of decision points, the performance of the approximation on the training
set, and the complexity of the approximation space. We believe further development of
this theory is needed to better understand how the performance of Q-learning with SVR
is related to the sample size of the training data in clinical reinforcement trials. We hope
that this dissertation will serve to stimulate interest in these issues.
In Chapter 5, we discussed some possible extensions of our method regarding the
right censored observations. We would like to briefly revisit this issue that arose and
discuss how it relates to more realistic problems in NSCLC clinical trials. We mentioned
that right censored cases include patients who drop out of the study without further
measurements, and we mentioned that the classical SVR method may need to be modified
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to -SVR-C to account for such right censored observations. By doing this, Q2 is fitted
with -SVR-C through:
Q2(o2, d2, TM) = T2 ∧ (C − t2), (6.1)
and furthermore, Q1 is fitted with -SVR-C through:
Q1(o1, d1) = T1 ∧ C ∧ t2 + YD × max
d2,TM
Q2(o2, d2, TM). (6.2)
This assumption of independent censoring may too simplistic to handle more complex
situations in NSCLC trials. For example, given first-line therapy, some patients determine
to drop out of the study due to adverse reactions or lack of improvement and are not
willing to participate the second-line therapy. However, these dropout patients can still
be followed-up until the patients’ death or administrative censoring. That is, O2 can not
be measured during this processes but TD or C can be. Such issues have motivated the
development of a possible alternative to the Q-learning procedure described in Chapter
5.
To achieve this alternative, we propose a modified Q-leaning design incorporated
with -SVR-C. Let D denote the indicator of a dropout event. D = 1 indicates patients
dropout at or before t2 without any measurements as well as without evaluation of second-
line therapy. In place of Q2 in (6.1), we then define Q
′
2 at t2 for patients who have status
D = 1, which is fitted with -SVR-C through:
Q
′
2(o1, d1) = T2 ∧ (C − t2). (6.3)
Compared to (6.1), o1 and d1 are embedded in Q
′
2. In addition, the corresponding Q1 is
modified as:
Q1(o1, d1) = T1 ∧ C ∧ t2
+ YD ×
[
D ×Q′2(o1, d1) + (1−D)× max
d2,TM
Q2(o2, d2, TM)
]
. (6.4)
Note that equation (6.4) is reduced to (6.2) when D = 0. This extension for accounting
for patients who dropout but who are followed would be conceptually straightforward if
98
the indicator D is observed. Thus, when D is unknown, a continuing challenge will be to
develop methods which model D efficiently to ensure that Q-learning is viable in these
settings.
In future research, we also plan to address the following issues:
(1) NSCLC clinical trial design. We will develop a protocol for a Stage IIIB/IV NSCLC
clinical reinforcement trial. This will include identifying and refining all of the
needed aspects which have been described in Chapter 5. Part of this process will
involve identifying what and how to randomize at various decision points in a
manner that is consistent with standards of clinical practice and avoids randomizing
to inferior treatments. This approach is quite new and may involve several iterations
before a suitable and efficient design is achieved.
(2) Adaptation to other cancers. The general principals and methods of this approach
are very adaptive to other cancers in addition to NSCLC, such as breast and colon
cancers, and we plan to develop general guidelines to pursue this. As part of this,
we expect to be able to start identifying specific other cancer treatment questions,
and then to use the differences between these cancers to formulate a general process
for developing reinforcement trials in a broad range of cancer settings.
(3) Creation of software tools. Clearly, we will develop user-friendly software to imple-
ment our reinforcement learning method freely for public use. We will also develop
software for the clinical trial design and analysis of clinical reinforcement trials. We
believe both of these phases will be valuable to other clinical researchers.
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